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The Swedish Governmental Commission
on Environment and Health (SOU 1996)
and the Governmental Committee on
Environmental Objectives (SOU 2000)
proposed, among other things, targets for
carcinogenic air pollutants in order to fulﬁll
the national objectives for the reduction of
harmful emissions to ambient air. However,
it was concluded that there was a need for a
better scientific basis for the selection of
chemical markers in ambient air to meet
the national objectives.
Against this background it was decided
by the Swedish Environmental Protection
Agency to commission The Institute of
Environmental Medicine of the Karolinska
Institute, to prepare an up-to-date review of
the carcinogenicity of polycyclic aromatic
hydrocarbons (PAHs), and to recommend
suitable indicator substances and guideline
values. The purpose was to create a list the
most important compounds, suitable for
ambient air monitoring, with regard to
source specificity, presence in ambient air,
and toxicity. 
This report has been prepared by an
expert group coordinated by Associate
Professor Katarina Victorin, The Institute of
Environmental Medicine (IMM). Coauthors
are Dr. Carl-Elis Boström and Dr. Titus
Kyrklund from the Swedish Environmental
Protection Agency, Associate Professor
Roger Westerholm from the Department of
Analytical Chemistry at Stockholm
University, and Associate Professor Christer
Johansson from the Environment and
Health Protection Administration of
Stockholm (“Sources, Deposition, and
Ambient Concentration” section); Associate
Professor Bengt Jernström, Dr. Per Gerde,
and Associate Professor Agneta Rannug from
IMM, and Associate Professor Margareta
Törnqvist from the Department of
Environmental Chemistry at Stockholm
University (“Mechanistic Aspects of Biologic
Activity”section); and Associate Professor
Katarina Victorin and Dr. Annika Hanberg,
IMM (“Quantitative Cancer Risk Estimates”
section). The document has been reviewed
and discussed by Professor Harri Vainio,
IMM/International Agency for Research on
Cancer; Associate Professor Per Gustavsson,
The Karolinska Hospital in Stockholm; and
Professor John Christian Larsen, Institute
for Food Safety and Toxicology, Søborg,
Denmark.
Nomenclature, Structure, 
and Sources of PAHs
Polycyclic aromatic hydrocarbons constitute
a wide class of compounds composed of
fused benzenoid rings (alternant PAHs), but
they may also be composed of unsaturated
four-, ﬁve-, and six-membered rings (nonal-
ternant PAHs). Within the group, the com-
pounds range from semivolatile molecules to
molecules with high boiling points. The
compounds may exist with a great number of
structures and, depending on the complexity
of the PAHs, in a large number of isomers.
The compounds are generally lipophilic, a
property that increases with increasing com-
plexity of the compounds (Harvey 1997).
In this context we mainly restrict our
discussion to unsubstituted PAHs, although
the compounds may exist in substituted
form (i.e., alkyl-, nitro-, amino-, or halogen-
substituted PAHs). PAHs are generally pro-
duced in incomplete combustion processes,
and their occurrence and emissions have
therefore been substantial during the past
centuries because of the abundant use of
fuels for industrial applications, heating,
transport, and many other purposes. Thus,
PAHs are ubiquitous contaminants in both
the general environment and in certain
working environments (IARC 1983,
1984a,b, 1985). The composition of the
PAHs emitted is dependent on a variety of
factors, for example, the fuel and its proper-
ties, and the combustion technology.
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Polycyclic aromatic hydrocarbons (PAHs) are formed during incomplete combustion. Domestic
wood burning and road trafﬁc are the major sources of PAHs in Sweden. In Stockholm, the sum
of 14 different PAHs is 100–200 ng/m3 at the street-level site, the most abundant being phenan-
threne. Benzo[a]pyrene (B[a]P) varies between 1 and 2 ng/m3. Exposure to PAH-containing sub-
stances increases the risk of cancer in humans. The carcinogenicity of PAHs is associated with the
complexity of the molecule, i.e., increasing number of benzenoid rings, and with metabolic acti-
vation to reactive diol epoxide intermediates and their subsequent covalent binding to critical tar-
gets in DNA. B[a]P is the main indicator of carcinogenic PAHs. Fluoranthene is an important
volatile PAH because it occurs at high concentrations in ambient air and because it is an experi-
mental carcinogen in certain test systems. Thus, fluoranthene is suggested as a complementary
indicator to B[a]P. The most carcinogenic PAH identiﬁed, dibenzo[a,l]pyrene, is also suggested
as an indicator, although it occurs at very low concentrations. Quantitative cancer risk estimates
of PAHs as air pollutants are very uncertain because of the lack of useful, good-quality data.
According to the World Health Organization Air Quality Guidelines for Europe, the unit risk is 9
× 10–5 per ng/m3 of B[a]P as indicator of the total PAH content, namely, lifetime exposure to 0.1
ng/m3 would theoretically lead to one extra cancer case in 100,000 exposed individuals. This con-
centration of 0.1 ng/m3 of B[a]P is suggested as a health-based guideline. Because the carcino-
genic potency of ﬂuoranthene has been estimated to be approximately 20 times less than that of
B[a]P, a tentative guideline value of 2 ng/m3 is suggested for fluoranthene. Other significant
PAHs are phenanthrene, methylated phenanthrenes/anthracenes and pyrene (high air concentra-
tions), and large-molecule PAHs such as dibenz[a,h]anthracene, benzo[b]fluoranthene,
benzo[k]fluoranthene, and indeno[1,2,3-cd]pyrene (high carcinogenicity). Additional source-
speciﬁc indicators are benzo[ghi]perylene for gasoline vehicles, retene for wood combustion, and
dibenzothiophene and benzonaphthothiophene for sulfur-containing fuels. Key words:
benzo[a]pyrene, carcinogenesis, comparative potency, concentrations in air, dose response,
ﬂuoranthene, indicator substances, mechanism of action, PAH, risk assessment. Environ Health
Perspect 110(suppl 3):451–489 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-3/451-489bostrom/abstract.html
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particles and undergo oxidation and degra-
dation in the atmosphere, processes activated
by ultraviolet radiation and enhanced by
other air contaminants. Because the best-
characterized individual source of PAHs is
vehicle emissions, this source is more exten-
sively treated in this document than wood
burning, which is the other major source.
PAHs and Human Carcinogenesis
The great interest in PAH compounds stems
from the observations that some of these
compounds may cause tumors in humans
(IARC 1983, 1984a,b, 1985). In fact, the
key event in this respect was the observation
in 1775 by the British surgeon Sir Percival
Pott that scrotal cancer in chimney sweeps
originates from occupational exposure to
soot (Pott 1775). This observation was fol-
lowed a century later by a report by von
Volkman (1875) on elevated incidences of
skin cancers in workers in the coal tar indus-
try. In the early 1900s it was widely recog-
nized that soot, coal tar, and pitch are
carcinogenic to man (Dipple 1985). More
recent animal experiments have shown that
the carcinogenic activity of PAHs in vehicle
exhaust extracts is associated mainly with the
fraction containing compounds composed of
four to seven aromatic rings (Grimmer et al.
1983, 1984). The International Agency for
Research on Cancer (IARC 1984a,b, 1985,
1987b, 1989a) has evaluated several different
PAH-containing materials or mixtures and
occupational situations in which exposure to
PAHs occurs. The overall evaluations are
summarized in Table 1. 
Thus, the carcinogenicity of PAHs and
PAH-containing materials in humans seems
to be beyond dispute. The carcinogenicity of
PAHs was demonstrated in 1915 (Phillips
1983), when it was shown that exposure of
the ears of rabbits to PAH-containing mater-
ial caused tumors at the site of application,
and a few years later such material proved to
be tumorigenic in mice by skin painting. In
the late 1920s, dibenz[a,h]anthracene was
synthesized and as the ﬁrst pure PAH proved
to be carcinogenic in the mouse. In the early
1930s an amount corresponding to a few
grams of benzo[a]pyrene (B[a]P) was isolated
from 2 tons of pitch and shown to cause
tumors in rodents (Dipple 1985; Phillips
1983). The frequent use of B[a]P as a model
compound for PAHs stems from this observa-
tion. A recent 2-year bioassay with mice
demonstrated that coal tar from gasiﬁcation
plant waste sites, mixed in the feed at
0.01–1% induced tumors in the liver, lung,
forestomach, and other organs. Parallel treat-
ment with B[a]P induced tumors of the
forestomach, esophagus, and tongue. A com-
parison of the results indicated that the lung
and liver tumors appeared to be due to other
genotoxic components in coal tar besides
B[a]P (Culp et al. 1998). Many PAHs have
been tested by topical application to the skin
of mice or by subcutaneous injection to iden-
tify the relationship between structural charac-
teristics of the compounds, their metabolism,
and tumorigenic potency. These factors are
discussed in detail in a separate section of this
document. Many PAHs are considered to be
complete carcinogens; thus the compounds
are both tumor initiators and promoters/pro-
gressors (for a definition, see “Mechanistic
Aspects of Biologic Activity”). Although ani-
mal experiments indicate that PAHs may also
give rise to, for example, immunologic and
reproductive effects (ATSDR 1995;
WHO/IPCS 1998), carcinogenicity is
regarded as the critical effect and is the
primary aspect considered in this document.
PAHs in Ambient Air
In Sweden, as well as in other countries, the
incidence of lung cancer is generally higher in
cities than in rural areas. Some of this cancer
is probably due to carcinogenic air pollutants,
although a higher rate of smoking in cities
and other factors also contribute (Ehrenberg
et al. 1985; Hemminki and Pershagen 1994;
Törnqvist and Ehrenberg 1994). For the
pollution levels prevailing around 1980, it
has been estimated that approximately 100
cases of lung cancer annually in Sweden (out
of 2,500) are related to carcinogenic air pol-
lutants that originate mainly from different
combustion sources (Swedish Cancer
Committee 1984).
The estimated cancer risk from air pollu-
tants is considered to be too high from the
national public health point of view. To
achieve the objective of reducing the emis-
sions, environmental quality objectives must
be deﬁned. The Governmental Commission
on Environmental Health (1996) proposed
such objectives for indicators of volatile and
nonvolatile carcinogens. For PAHs the pro-
posal was that by 2020 the long-term mean
level of B[a]P should not exceed 0.1 ng/m3.
This level is equivalent to a theoretic excess
lifetime cancer risk of 1 in 100,000 (1 ×
10–5) for B[a]P as an indicator of PAH,
based on a risk assessment by the World
Health Organization (WHO) (1987). This
long-term objective was later adopted by
Government Bill 2000/01:130 (Swedish
Government 2000). 
Although B[a]P has been used histori-
cally as an indicator of carcinogenic PAHs
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Table 1. IARC evaluations of certain complex mixtures and occupational exposures involving exposure to
PAH compounds.a
IARC classiﬁcation
Group 1: Group 2A:  Group 2B: 
carcinogenic probably carcinogenic  possibly carcinogenic  Group 3: 
Mixture/exposure to humans to humans  to humans  not classiﬁable
Bitumen X
Bitumen extracts X
Carbon black X
Carbon black extracts X
Coal dust X
Coal tar pitches X
Coal tars X
Creosotes X
Crude oil X
Diesel fuels
Light X
Marine X
Fuel oils
Heavy X
Light X
Gasoline X
Jet fuel X
Mineral oils
Untreated X
Mildly treated X
Highly reﬁned X
Petroleum solvents X
Shale oils X
Soots X
Diesel exhausts X
Gasoline exhausts X
Tobacco smoke X
Aluminum production X
Coal gasiﬁcation X
Coke production X
Petroleum reﬁning X
aData from IARC 1984a,b, 1985, 1987a, 1989a,b.and PAH derivatives, the suitability of B[a]P
as an indicator has been questioned, mainly
because the most-cited quantitative risk
assessment is based on an increased risk of
lung cancer among coke-oven workers. The
PAH profiles of relevant emissions today
(traffic exhausts, wood combustion, and
other combustion sources) probably differ
from those of coke-oven emissions with
regard to the relative contribution of B[a]P,
other PAHs, and PAH derivatives. In ambi-
ent air the concentration of B[a]P is
relatively low compared with other PAHs.
The Goals of This Study
Because there might be other PAH com-
pounds besides B[a]P that could be equally
or more suitable for risk assessment and as
indicator substances, the Swedish
Environmental Protection Agency asked the
IMM to discuss the suitability of different
possible indicators from a scientiﬁc point of
view and to come up with proposals both for
indicator substances and for guideline values.
The authors of this report with represen-
tatives from the emission–imission–analytic
side and the toxicologic-risk assessment side
identiﬁed some characteristics for good indi-
cators: a) they should ideally be important
health risk factors; b) it should be possible to
quantify the risk contribution from the indi-
cator; c) they should include both source-
specific indicators and general indicators of
ambient air pollution; d) both particulate-
phase and vapor-phase PAHs should be rep-
resented; and e) it must be possible to analyze
them chemically with high reproducibility.
The authors agreed that possible options
for indicator substances should be thor-
oughly discussed, taking into account the
different aspects, and realized that it might
be difficult to find a single indicator that
would fulﬁll all these demands.
At an early stage the group also decided
that the review should be restricted to
unsubstituted PAH compounds. PAH deriv-
atives are also important, especially because
the highest mutagenic activity in short-term
tests is usually found in the more polar frac-
tions of environmental samples that contain,
for example, nitrated, oxygenated, and
hydroxylated PAHs. However, much less is
known about the chemical identiﬁcation and
toxicologic effects of PAH derivatives than
about unsubstituted PAHs.
The intention of the present work has
been to highlight certain mechanistic aspects
of the carcinogenicity of PAHs and to con-
duct risk assessment, with the focus on the
comparative quantitative potency of differ-
ent PAHs. The assignment also included a
survey on how risk assessment and indicators
of PAHs in ambient air have been dealt with
in other countries. The authors recommend
the recent International Programme on
Chemical Safety (IPCS) Environmental
Health Criteria document on PAHs as the
main reference book (WHO/IPCS 1998).
Sources, Deposition, and
Ambient Concentrations
Sources
National data on emissions of PAHs are lim-
ited. Data from European countries are pre-
sented in Table 2 (Berdowski et al. 1997;
EEA CORINAIR 1997; Pacyna 1999). The
emission estimates regarding PAHs are gen-
erally more uncertain than for other pollu-
tants such as nitrogen dioxide or sulfur
dioxide because of less-developed method-
ologies for their quantification and less-
frequent measurements of PAHs in urban
air. In addition, there may be differences in
the number of PAHs reported and the
sources included in the estimates from vari-
ous countries. The contribution from differ-
ent sources such as residential heating,
automobile exhaust, industrial power genera-
tion, incinerators, and the production of coal
tar, coke, and asphalt is difﬁcult to estimate.
These estimates may also vary considerably
from country to country. In the United
States and also in Sweden, residential burn-
ing of wood is regarded as the largest source
of PAHs. However, in cities, mobile sources
including working machinery contribute to
the major part of the PAH emissions. The
main source sectors in 1994 are given in
Table 3. A recent emission inventory for
Sweden is presented in Table 4. There was a
reduction in the emission of PAHs in
Europe from the 1960s to the 1980s, and
the concentrations of PAHs in cities also
declined during the same period. However,
the data are uncertain. Data from Sweden
indicate that the emissions of PAHs were
reduced by 35% between 1980 and 1987
and by 15% between 1987 and 1995
(Boström 1997; SEPA 1996a).
Road transport. In general, automotive
exhaust is an important emission source that
contributes substantially to urban air pollu-
tion. In all nonideal combustion processes of
organic fuels, compounds other than carbon
dioxide and water will be formed in different
amounts. Emissions of speciﬁc PAHs can be
associated with particulates; they can be pre-
sent in the gas phase; or they can be present
in mixtures of both forms. Emissions from
automobiles comprise regulated and unregu-
lated exhaust emissions. Regulated emissions
by law are carbon monoxide, nitrogen
oxides, unburned fuel hydrocarbons, and
particles. Nonregulated pollutants are
deﬁned as compounds not speciﬁed by law.
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Table 2. Emissions estimates from European
countries—anthropogenic emissions of PAHsa
(tonnes/year) in the EU region.
PAHb PAHc B[a]Pd
Country (1994) (1990) (1995) 
Austria 458 243 6.11
Belgium 818 3.35
Denmark 37 76.7 1.44
Finland 104 6.88
France 3,479 26.4
Germany 420 420 26.4
Greece 153 2.89
Ireland 73.7 1.24
Italy 694 13.9
Luxembourg 1.1 6.24 0.24
Netherlands 184 2.29
Norway 181
Portugal 138 1.64
Spain 521 9.61
Sweden 153 282 6.78
United Kingdom 764 1,437 12.0
aPAHs refers to the “Borneff six” (benzo[a]pyrene,
benzo[b]fluoranthene, benzo[ghi]perylene, benzo[k]fluo-
ranthene, fluoranthene, and indeno[1,2,3-cd]perylene).
bData from EEA CORINAIR (1997). cData from Berdowski
et al. (1997). dData from Pacyna (1999).
Table 3. Main source sectors for PAHs in 1994 (tonnes/year) in six European
countries as reported in Table 2 (Sweden excluded).a
Sector PAH %
Combustion in energy and transformation industries 6.1 0.3
Nonindustrial combustion plants b 1,120 60
Combustion in manufacturing industry 63 3.4
Production processes 248 13
Road transport 383 20
Other mobile sources 10 0.5
Waste incineration  30 1.6
Agriculture and forestry 1 <0.1
Natural sources  8 0.4
Total (approximately) 1,900
aData from EEA CORINAIR (1997). bIncludes domestic wood burning.
Table 4. Emissions to air of PAHs (tonnes/year) in Sweden.a
Sources 1990 1992 1995
Graphite and aluminum works b 23 2 2
Domestic heating c 108 101 101
Transport and working machinery 50 50 50
Waste incineration 0.9 0.4 0.3
Total 182 153 153
aData from Boström (1997). bGraphite production ceased in 1991. cIncluding wood burn-
ing and district heating.However, these may well be included in
the group of unburned hydrocarbons. The
total number of exhaust constituents is
estimated to be more than 20,000 individ-
ual chemical compounds (U.S. EPA 1990),
and consequently it is not feasible to
quantify all of them. 
In automotive exhaust several important
groups of compounds are emitted that may
have a negative impact on health. Among
these are aldehydes, some of which have irri-
tant and also carcinogenic effects; alkenes,
some of which form highly carcinogenic
metabolites; monoaromatic compounds,
among which benzene, toluene, cresols, and
phenols are of special interest; and the broad
group of polycyclic aromatic compounds,
several of which are suspected carcinogens.
Following the introduction of combustion
engines of Otto and diesel types, motor vehi-
cles have become important contributors to
air pollution, and they also constitute a
health risk with respect to emissions of
PAHs, especially in densely populated areas.
The exhaust PAHs emitted from auto-
mobiles are present in the gaseous phase as
well as associated with particles (Westerholm
and Egebäck 1994). As a consequence,
PAHs from vehicles are determined in the
urban environment as “particle associated”
and “semivolatile” (Bidleman 1988; Pankow
1987; Thrane and Mikaelsen 1981), and
both PAHs associated with particles and
those occurring in the gaseous phase must be
considered when marker compounds are
chosen. Two extremes are phenanthrene,
which is present to approximately 95% in
the gaseous phase, and coronene, which is
almost completely present in the particle
phase. Sampling techniques must be further
developed and combined with analytic
methodologies to ensure that methods avail-
able for monitoring individual PAH emis-
sions are relevant with respect to risk
assessment.
Vehicle exhaust is the largest contributor
to PAH emissions in central parts of large
cities. It is well known that PAH emissions
from vehicles depend on several factors such
as fuel type (Egebäck and Bertilsson 1983;
Lies 1989), fuel parameters (Sjögren et al.
1996a), driving conditions (Rijkeboer and
Zwalve 1990), ambient temperatures
(Laurikko and Nylund 1993), exhaust after
treatment devices (Egebäck and Bertilsson
1983), and engine adjustment (Rijkeboer
and Zwalve 1990). PAH proﬁles from differ-
ent vehicle concepts are presented in Table 5
and Figures 1–3. The total PAH emissions
decrease by at least a factor of 5 on changing
from the nonenvironmentally classiﬁed fuel
(MK3) to the environmentally classified
diesel fuel (MK1) (Table 5). 
MK1s have been available in Sweden
since 1991. Fuels of this class emit less PAHs
than previous MK3s (Grägg 1994;
Westerholm and Egebäck 1991). By using
MK1, PAH profiles are shifted toward
smaller three-ringed PAHs, significantly
reducing the relative contributions of B[a]P
or larger PAHs. Emissions from gasoline and
diesel passenger cars were compared (Almén
et al. 1997; Lenner and Karlsson 1998). In
conclusion, the specific emissions of PAHs
from modern cars were observed to be 5
times higher from diesel engines than from
gasoline cars during transient driving condi-
tions. Older diesel cars and gasoline cars
with a catalytic converter of outmoded
design have 5–10 times higher PAH emis-
sions than modern cars. In North European
cities, cold-start emissions from gasoline
vehicles are of considerable importance
because they may account for more than
50% of the total PAH emissions from gaso-
line vehicles (Lenner and Karlsson 1998).
Using the emission factors by Lenner and
Karlsson (1998) and the 1994 statistics for
vehicle use, the emissions of B[a]P can be
estimated (Table 6).
In addition to vehicle exhaust, resus-
pended road dust from wear of tires and
asphalt may also contribute to the PAH
levels in ambient air (Ahlbom and Duus
1994; WHO/IPCS 1998). Ahlbom and
Duus (1994) estimated that the emissions
in Sweden of B[a]P from road and tire
wear were 45 and 60 kg per year, respec-
tively (Table 6). However, this PAH is
probably associated mainly with coarse
particles (>10 µm).
Industry and energy production. In
Sweden the most important industrial
processes suspected of emitting PAHs are
aluminum smelters, coke production, the
manufacture of asphalt or rubber products,
and energy production from oil, coal and
various fuels of biomass origin. However, the
only industrial sources that have been char-
acterized are emissions from aluminum
smelters and the production of graphite elec-
trodes, of which the latter was stopped in
1990 (Table 4). Emissions from asphalt and
the rubber industries are not known in detail
in Sweden. However, emissions of about 50
tonnes annually of PAH-containing smoke,
formed during the vulcanization process of
rubber, have been reported (SEPA 1995).
These two latter sources may contribute
additional emissions of PAHs. Energy con-
versions by combustion of oil, coal, coke,
and different biofuels may also contribute to
the emissions of PAHs. However, different
industrial sources are not as well character-
ized with regard to PAH emissions as mobile
sources. 
Domestic heating. Westerholm and
Peterson (1994) presented a comparison of
PAH emissions from domestic oil heating
with PAH emissions from diesel-fueled
vehicles in Sweden. It was concluded that
annual PAH emissions from domestic oil
heating were approximately 20% of the
emissions from diesel vehicles. An important
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Table 5. Comparison between examples of different vehicle types with regard to PAH emissions (µg/km)
of quantitative importance during transient driving conditions. 
Light-duty vehicles Heavy-duty trucks
Gasolineb,c Dieselb,c Dieselb,d Dieselb,d
Gasolinea,b with (MK1) with (MK3) (MK1)
without three-way oxidizing without without
catalytic catalytic  catalytic  catalytic  catalytic 
Individual PAHs converter converter converter converter converter
2-Methylﬂuorene ND 1 2 37 2
Dibenzothiophenee ND <0.1 1 10 3
Phenanthrene 91 28 38 267 40
Anthracene 28 5 3 28 3
2-Methylphenanthrene ND 0.3 1 166 8
2-Methylanthracene ND 2 6 154 10
1-Methylphenanthrene 16 1 6 99 10
Fluoranthene 21 5 33 83 24
Pyrene 22 3 25 212 70
2-Methylpyrene <0.1 <0.1 0.3 10 1
Benzo[ghi]ﬂuoranthene 4 0.5 1 1 <0.1
Cyclopenta[cd]pyrene 3 1 0.3 0.2 <0.1
Benzo[a]anthracene 4 0.4 0.5 4 <0.1
Chrysene/triphenylene 4 1 1 1 0.2
Benzo[b and k]ﬂuoranthene 5 1 0.4 0.5 <0.1
Benzo[e]pyrene 3 0.2 0.3 <0.1 <0.1
B[a]P 6.6 0.3 0.1 0.2 <0.1
Indeno[1,2,3-cd]ﬂuoranthene <0.1 <0.1 <0.1 <0.1 <0.1
Indeno[1,2,3-cd]pyrene 2 0.4 0.1 <0.1 <0.1
Dibenzo[a,h]anthracene ND <0.1 <0.1 <0.1 <0.1
Benzo[ghi]perylene 6 0.5 0.2 <0.1 <0.1
Coronene 2 0.5 0.1 <0.1 <0.1
ND, not determined. aWesterholm et al. (1988). bIncludes both particle-associated and gas phase–associated PAHs.
cAlmén et al. (1997). dGrägg (1995). eContains sulfur, i.e., S-PAH.contributor to PAH emissions, especially in
wintertime in Sweden, is domestic heating
by wood burning (Camner et al. 1997).
Sweden differs from many other countries
regarding the burning of wood. Most fre-
quently, wood is burned in boilers con-
structed for multiple energy sources (oil,
wood, electricity). Today, however, low-
emitting boilers have been introduced onto
the market. Lately, stoves have come into
use increasingly as an additional heating
device, often in urban areas. Emissions from
wood combustion consist mainly of particu-
late matter, tar, and volatile compounds.
Because the combustion is very often inefﬁ-
cient, large quantities of organic matter are
emitted. The emission of particles ranges
from 200 to 1,500 mg/MJ in older Swedish
investigations on wood-fired boilers under
different conditions (Camner et al. 1997).
Larsen (1991) reports that, based on the
available international literature, 530 mg/MJ
is a reasonable average for wood-ﬁred boilers
and stoves. The composition of the particles
is not known in detail. Tar consists of a great
number of condensable organic compounds,
among which the PAHs are an important
group. The reported specific emissions of
PAHs vary considerably (Table 7). 
In older Swedish studies, values between
1,400 and 8,300 µg/MJ have been reported
(Rudling et al. 1980). The pattern of indi-
vidual PAHs in wood-ﬁre emissions covers a
wide molecular weight range similar to that
from mobile sources (Tables 5 and 8).
Larsen (1991) looked at a number of investi-
gations from different countries and con-
cluded that 2,900 µg/MJ was a reasonable
average for PAH emissions from small-scale
wood-heating devices currently in use.
Emissions from a low-emission type of boiler
are considerably lower (50–150 µg/MJ) than
those from the standard types (SEPA
1996b). However, at present less than 10%
of the boilers in use are of low-emission
type. One important difference when com-
paring emissions from traffic with those of
domestic wood burning is that emission data
from wood boilers are not given for the
whole emission cycle, including the startup
period. This may be important when calcu-
lating emissions from modern low-emission
boilers if the boiler is not in continuous use. 
If the average winter mean concentra-
tions of soot and nitrogen dioxide from an
urban and a background site are compared,
it can be determined that the concentrations,
relative to the background level, are larger
for soot than for nitrogen dioxide in areas
where residential wood burning is believed
to be common, namely, in northern Swedish
towns. It can thus be suspected that the con-
tribution to the local environment of soot
particles from residential wood heating in
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Figure 1. PAH emission proﬁle, diesel-fueled heavy-duty truck, MK3, without oxidizing catalytic converter. Data from
Grägg (1995).
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Figure 2. PAH emission proﬁle, diesel-fueled heavy-duty truck, MK1, without oxidizing catalytic converter. Data from
Grägg (1995).
Figure 3. PAH emission proﬁle, gasoline passenger car with three-way catalytic converter. Data from Almén et al.
(1997). 
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perhaps exceeding that of other sources such
as trafﬁc. 
Although the number of wood-heated
houses is relatively small in urban areas,
those houses may account for as much as
25% of the total wood consumption for
heating purposes (SEPA 1993). Thus, the
problem with emissions from wood combus-
tion for domestic heating may not be
restricted only to the small cities in northern
Sweden, as is usually believed.
The total use of wood for domestic heat-
ing in Sweden was estimated to be between
2.1 and 2.8 megatonnes/year in 1994, which
is comparable to a production of 12 TWh
energy (SNBITD 1995). The use of oil for
domestic heating in 1994 was about 32
TWh (SNBITD 1995). Using the emission
factors in Table 7, the emissions of B[a]P
can be calculated for Sweden for 1994. The
yearly emission of B[a]P from wood burning
is approximately 430 kg and is less than 1 kg
from residential oil heating (Table 6). The
total emissions for PAHs are estimated to be
about 100 tonnes/year from domestic wood
burning, with a minor contribution from
residential oil heating. According to these
estimates, wood combustion dominates the
PAH emissions in Sweden. This is consistent
with other investigations, but large variations
in emission factors, and thus emission esti-
mates for PAHs, are evident (Larsen 1991).
This large spread in the data implies a con-
siderable uncertainty in emission factors, but
there are also large uncertainties in the esti-
mated amount of wood used for burning. 
Concentrations in Ambient Air
Polycyclic aromatic hydrocarbons can be
transported over long distances, and measur-
able atmospheric concentrations can be
found throughout the world, even in very-
remote areas. A number of studies on marine
and lake sediment proﬁles show a good asso-
ciation between the sediment levels of PAHs
and the onset of widespread fossil fuel com-
bustion. The natural background level is
inﬂuenced by forest ﬁres, for example, but is
normally believed to be very low. Data on
the sources, fate, and degradation of PAHs
are extensively covered in a review by
WHO/IPCS (1998).
Gas/particle partitioning of polycyclic
aromatic hydrocarbons. A large fraction of
the deposition of PAHs in Sweden depends
on long-range transport from other parts of
Europe. The airborne PAHs are subse-
quently deposited on the ground, on vegeta-
tion, or on other ground surfaces. Of special
interest regarding human exposure is the
deposition on food crops, which may be an
important source of PAH intake in humans.
The principal mechanisms for removal of
PAHs from the atmosphere are deposition
and (photo)chemical transformation. Both
dry and wet deposition of gaseous and par-
ticulate PAHs may be important. The parti-
tioning of different PAHs between gas and
particle phases regulates the efficiency of
removal from, and transport to, the atmos-
phere. Rain scavenging and dry deposition
processes are highly dependent on the rela-
tive amounts present in the gas and particle
phase. In addition, the size distribution of
the particles is important for the efﬁciency of
wet and dry deposition. 
The partitioning of PAHs between gas
and particle phases depends on the ambient
temperature, relative humidity, the proper-
ties and the concentration of PAHs, and on
the chemical composition of the aerosol par-
ticles (Goss and Schwarzenbach 1998).
Semiempiric partitioning constants have
been used to estimate the partitioning
(Pankow 1991). As a rule of thumb, Baek et
al. (1991) proposed that two- and three-ring
PAHs are mainly in the gas phase, four-
ringed PAHs are in both gas phase and parti-
cle phase, and ﬁve- and six-ringed PAHs are
mainly attached to particles. An example of
this distribution in urban ambient air sam-
ples is shown in Figure 4 (Svanberg 1997).
Particulate PAHs are observed predomi-
nantly in fractions of fine particles with a
diameter ranging between 0.01 and 0.5 µm.
Venkataraman and Friedlander (1994) mea-
sured a bimodal mass distribution of PAHs
with a second mode between 0.5 and 1 µm
in an urban aerosol. Different sources may
generate PAHs containing particles of differ-
ent sizes. Miguel et al. (1998) showed that
most of diesel-derived PAHs were present in
both an ultraﬁne size mode (<0.12 µm) and
in the accumulation size mode (0.12–2 µm),
whereas gasoline engine-derived PAHs were
almost entirely in the ultraﬁne mode. 
Chemical transformations of PAHs.
Chemical reactions may occur both with
gaseous and particulate PAHs. Such reac-
tions may involve either ozone, hydroxyl
radical, NO2, or HNO3. In general this
leads to the formation of more polar and
more water-soluble PAH derivatives, for
example, compounds substituted with nitro-
or hydroxyl- groups. The chemical transfor-
mation rate, with half-lives reported in
ranges from hours to days, depends on a
number of factors. For example, PAHs
bound to particles with high organic carbon
contents may be much more stable than if
the same compound is in the gas phase. The
concentrations of ozone and OH are also
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Table 6. Estimated emissions to air of PAHs (tonnes) and B[a]P (kg) from
different sources in Sweden, 1994.
PAH Gasoline Diesel  Wood  Residential Tire  and
compound vehicles vehicles burning  oil  heating  road wear
B[a]P 150a (300)b 20a 430c <1c 100
PAH 61a (11)b 4a 60–200d nd nd
nd, no data. aBased on emission factors from Lenner and Karlsson (1998) and total driving
distance for different vehicles in Sweden in 1994. Data on total driving distance are as
follows: a) gasoline vehicles: passenger cars without and with catalytic converter, 27.4 ×
10–9 km and 28.3 × 10–9 km, respectively; b) light-duty trucks without and with catalytic
converter, 1.79 × 10–9 km and 0.55 × 10–9 km, respectively; c) diesel vehicles: passenger
cars, 2.36 × 10–9 km; light-duty trucks, 0.44 × 10–9 km; heavy-duty trucks, 3.31 × 10–9 km;
buses, 0.85 × 10–9 km (Swedish National Road and Transport Institute 2000). bEstimate
including cold start. cA lower-range estimate based on an example of a well-working
boiler, Table 8. dData from Camner et al. (1997).
Table 7. Typical emissions from wood boilers.
Dry wooda Dry wooda Low-
(excess (restricted  Dry Literaturec emissiond
Emission air) air) woodb average boiler
Particles (mg/MJ) 200 700 1,500 530 nd
Tar (mg/MJ) 130 500 nd nd nd
PAH (µg/MJ) 1,400 8,300 5,000 2,900  50–150
B[a]P (µg/MJ) 10 200 30 nd nd
nd, no data. aData from Rudling et al. (1980). bData from Ahlborg et al. (1990). cData from
Larsen (1991). dData from SEPA (1996b). 
Table 8. Emissions of PAHsa from domestic
burning of wood and oil (µg/MJ). 
PAH compound Woodb Oilc
Phenanthrene 690 1.3
Anthracene 97 0.03
Fluoranthene 148 0.09
Pyrene 114 0.02
1-Methylpyrene ND 0.05
Benzo[b]ﬂuorene ND 0.1
Benzo[ghi]ﬂuoranthene 22 ND
Cyklopenta[cd]pyrene 23 ND
Benzo[a]anthracene 37 <0.003
Chrysene/triphenylene ND <0.003
Benzo[b and k]ﬂuoranthene 7 <0.003
Benzo[e]pyrene 5 ND
Benzo[a]pyrene 10 <0.003
Indeno[1,2,3-cd]pyrene 3 ND
Dibenzo[a,h]anthracene ND <0.003
Benzo[ghi]perylene 3 ND
Coronene <1 ND
ND, not determined. aIncludes both gas-phase and
particle-bound PAHs. bData from Rudling et al. (1980).
Standard boiler with excess air. cData from Bardh and
Ahling (1983). Standard boiler with a clear, nonsmoking
ﬂame.important, and they depend on the levels of
precursors (NOx and volatile hydrocarbons)
and on a number of meteorologic factors.
During winter at high latitudes, with rela-
tively little solar radiation and low tempera-
tures, photochemical oxidation processes
will be less important. PAHs may also
(re)volatilize from soils and water.
Background air concentrations and
deposition of PAHs. Measurements of
PAHs in ambient air have been performed
since the end of the 1980s at Rörvik, a
background measurement station on the
west coast of Sweden. In cooperation with
Finland, there is also one measurement sta-
tion at Pallas in the north of Finland
(Table 9). At these stations, PAH concen-
trations in air and deposition rates are
measured by the same methods. The PAH
determination includes 11 components:
phenanthrene, anthracene, fluoranthene,
pyrene, benz[a]anthracene, chrysene,
benzo[b]fluoranthene, benzo[k]fluoran-
thene, benzo[a]pyrene, benzo[ghi]perylene,
and indeno[cd]pyrene. The background
deposition of PAHs at Rörvik shows no
trend with time. Furthermore, there is no
simple relationship between the deposition
and the air concentration. The mean air
concentration of PAHs at Rörvik, gas and
particle phases combined, was around 4
ng/m3 (range 2.2–5.5) and for B[a]P 0.09
ng/m3 (range 0.06–0.12) for 1995–1998
(Table 9). There is a tendency for the con-
centrations to decrease. At Pallas in north-
ern Finland, concentrations are lower by a
factor of 3–5. 
Urban air concentrations of PAHs.
About 500 PAHs have been detected in air,
but often the measurements include only
B[a]P as representative of the whole PAH
group. It is difficult to compare different
measurements, as sampling and analysis
methods often differ, especially when
comparing older data with recent measure-
ments. In the 1960s, the B[a]P levels were
sometimes higher than 100 ng/m3 in many
European cities, but during the past 30
years, concentrations in urban ambient air
have decreased considerably. A survey of
international studies has recently been
published by WHO/IPCS (1998). 
Stockholm. Since 1991, the Environ-
ment and Health Protection Administration
of Stockholm has carried out measurements
at Hornsgatan in the center of Stockholm
(Johansson et al. 1999). The measurements
are made during the spring (April and May),
at 3 m above street level. Figure 5 shows the
PAH levels for the sum of 14 PAHs ranging
from 100 to 200 ng/m3 (Burman 2001).
The B[a]P levels were between 0.4 and 2
ng/m3. The relative abundance of the main
PAHs at Hornsgatan during 1996 are shown
in Figure 6. These 15 PAHs make up more
than 90% of the total amounts of PAHs
measured at this site (34 different com-
pounds). The most abundant PAH is
phenanthrene, which constitutes 24% of the
total amount. The quantitative cancer risk
estimates presented in “Quantitative Cancer
Risk Estimates” later in this document show
that of the PAH measured in urban air,
ﬂuoranthene may be an important contribu-
tor to cancer risk due to ambient air expo-
sure. The measurements in Stockholm (at
Hornsgatan during spring of 1994–2000)
have shown ambient air concentrations rang-
ing from 8 to 25 ng/m3. The quotients of
ﬂuoranthene to B[a]P have ranged from 7 to
25 with a median value of 13.
The concentrations of PAHs at roof level
in central parts of Stockholm are approxi-
mately 10–15 ng/m3. It is important to note
that these data also include the volatile PAH
fraction and not only the PAH bound to
particles (Johansson et al. 1999). 
It is difficult to establish any trend in
composition or in levels of individual PAHs
over time because data have only been avail-
able for limited periods of the year.
However, the data presented in Figure 5 for
central Stockholm indicate that the levels
are decreasing. This is qualitatively consis-
tent with lower vehicle exhaust emissions,
which are due to increased use of catalytic
converters and MK1. Generally the PAH
levels are higher during the winter season
than during the summer. This is because of
higher emissions from combustion sources,
more frequent periods with less-efficient
atmospheric mixing, and increased residence
time in the air due to decreased degradation
of PAHs. Data from measurements in
Stockholm indicate the presence of more
low-molecular PAHs in winter than in sum-
mer (EHPA 1984; Östman et al. 1991).
This could be because of higher emissions of
these PAHs from residential heating during
the winter. There are, however, very little
data for comparison of the levels between
different seasons. 
In a series of measurements in Stockholm
during 1980–1983, large differences in PAH
levels between different streets were observed
that could not easily be related to more
intense traffic or other differences in PAH
emissions (EHPA 1984). These differences
could have been due to a number of factors,
including different street widths, heights of
houses, and street direction compared with
wind direction during sampling as well as to
different sampling periods. 
Gothenburg. In the project “Air
Pollution in Urban Areas,” investigations
concerning particle-bound PAHs were per-
formed from 1984 to 1987 in the
Gothenburg area of Sweden (Boström et
al. 1994; Brorström-Lundén and Lindskog
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Table 9. Measured deposition and air concentra-
tions of PAHs at two background measurement
stations in Sweden and Finland.
Deposition 
Air (ng/m3) (µg/m2/year)
Sum of  Sum of 
Year 11 PAHs B[a]P 11 PAHs B[a]P
Rörvik, Sweden
1994 2.9 0.072 115 4.4
1995 5.5 0.12 96 4.0
1996 4.1 0.095 143 3.9
1997 3.6 0.10 135 6.4
1998 2.2 0.065 84 3.8
Pallas, Finland
1996 0.87 0.015 17 0.83
1997 0.78 0.021 18 0.67
1998 0.85 0.017 61 2.0
aBrorström-Lundén et al. (2000).
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Figure 4. The distribution of individual PAHs to particles (PM2.5) and gas phase in a single ambient air sample. Data
from Svanberg (1997).1985; Löfroth et al. 1990; Steen 1985).
However, these invesigations occurred
before the introduction of MK1 and cat-
alytic converters in gasoline-driven cars.
Thus, the ambient air concentration of
PAHs in Gothenburg today is expected to
be lower. In this project, samples were
taken in the urban background, at street
level with high and low traffic, and in sub-
urban areas. Particles were sampled for 2
days with a high-volume sampler at each
place, and the measurements were repeated
according to a scheme during 18 months at
the different sampling places to obtain a
representative mean value for the concen-
tration of PAHs in the Gothenburg area.
The PAH content of the particles was ana-
lyzed for 14 selected individual PAHs. The
median level of all measured PAHs (sum of
14) concentrations in the particulate phase
was 6.1 ng/m3 (range 0.6–100 ng/m3).
The PAHs detected ranged from phenan-
threne (mw 178) to coronene (mw 300).
At street level the median in a busy street
was 12 ng/m3 (range 1–64 ng/m3), and in
a street with less traffic, 5.7 ng/m3 (range
0.6–42 ng/m3). At street level the concen-
tration in air of B[a]P was 0.39 ng/m3
(range 0.12–1.6 ng/m3). A seasonal varia-
tion by a factor of 3–5 in winter and sum-
mer was determined for the PAH
concentration of ambient air samples in
Gothenburg. In a recent investigation
regarding PAHs in both the particle and
gaseous phases, the relative distribution of
PAHs in urban background air in
Gothenburg was similar to that in
Stockholm (Svanberg 1997).
Selection of Marker PAHs from
Emission and Immission Data
To date, there has been no clear interna-
tional agreement on which individual PAHs
should be reported concerning emission and
immission of PAHs. The first attempt to
standardize matters was made by the WHO
for the analysis of drinking water (Borneff
and Kunte 1979; WHO 1971). Six PAHs,
namely fluoranthene, B[a]P, benzo[b]-
ﬂuoranthene, benzo[k]ﬂuoranthene, indeno-
[1,2,3-cd]pyrene, and benzo[ghi]perylene,
were suggested for reasons concerning
chemical analysis. 
The Expert Panel on Heavy Metals and
Persistent Organic Pollutants, established
within the UNECE (United Nations
Economic Commission for Europe) Task
Force on Emission Inventories, proposed at
a workshop in Regensburg, Germany, in
May/June 1994 that the following PAHs
be considered in its further work, namely
benz[a]anthracene, benzo[b]fluoranthene,
dibenz[a,c]anthracene, dibenz[a,h]-
anthracene, B[a]P, chrysene, fluoranthene,
phenanthrene, naphthalene, anthracene,
and coronene. This decision was based on
the relative occurrence in the environment
of the different PAHs and their general
toxicity to the environment.
The following PAHs are common to the
two proposals above: fluoranthene, B[a]P,
and benzo[b]ﬂuoranthene. These two exam-
ples show the difficulties in selecting PAHs
for reporting. In the review by WHO/IPCS
(1998) PAHs recommended for quantifica-
tion by various authorities are listed.
To investigate important PAHs repre-
senting different mobile sources such as
gasoline-fueled and diesel-fueled light-duty
vehicles and heavy-duty vehicles, investiga-
tors conducted principal component analy-
sis. Emissions data from light and heavy
diesel and gasoline vehicles at different start-
ing temperatures (–7°C and 22°C) were
analyzed for their similarities and differences
(Almén et al. 1997; Grägg 1994). 
In summary, PAHs of lower molecular
weight were characteristic of heavy diesel
vehicles, fluoranthene (mw 202) and
pyrene (mw 202) being most important.
Characteristic PAH indicators for the light-
duty diesel vehicle were 2-methylpyrene,
pyrene, 1-methylpyrene, benzo[ghi]ﬂuoran-
thene, and chrysene/triphenylene. For light-
duty gasoline vehicles without catalytic
converters, PAHs larger than cyclopenta[cd]-
pyrene were characteristic, for example,
coronene. For gasoline cars with catalytic
converters the total emissions of PAHs were
quantitatively much lower, but there was
only a small change in the pattern of individ-
ual PAHs. Because a covariation exists
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Figure 6. The 15 most abundant PAHs at Hornsgatan (Stockholm city) from April to June 1996. The levels indicated
are the sum of particulate and semivolatile PAHs. Data from Johansson et al. (1999).
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Figure 5. Concentrations of 14 PAHs (sum of gaseous and particle-bound PAH) at Hornsgatan in central Stockholm.
Note that the measurements were taken during only 2 months (April and May) each year (Burman 2001).
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Yearamong many PAHs, it might be possible to
reduce the number of measured PAHs
without losing too much information. A
suggestion for the selection of PAHs, com-
paring different vehicles, would be diben-
zothiophene, phenanthrene, 2-methyl
anthracene, fluoranthene, pyrene, B[a]P,
benzo[b]fluoranthene, benzo[k]fluoran-
thene, indeno[1,2,3-cd]pyrene, benzo[ghi]-
perylene, and coronene. 
When the different mobile sources as well
as wood burning sources are compared on a
quantitative basis, as in Tables 5 and 7,
phenanthrene, anthracene, fluoranthene,
pyrene, and chrysene are representative for all
sources. Speciﬁc markers for diesel engines are
difﬁcult to specify. To some extent, gasoline
cars can be represented by benzo[ghi]perylene.
Retene (1-methyl 7-isopropyl phenanthrene)
has been suggested as a marker PAH for the
burning of wood (Ramdal 1983). However,
this marker seems applicable only for emis-
sions from the burning of softwood
(McDonald et al. 2000).
Ambient air is dominated by smaller
PAHs, as for example, phenanthrene,
pyrene, and fluoranthene (Figure 6). These
PAHs are thus of great importance for
human exposure and must therefore be rec-
ommended as marker compounds.
In summary, phenanthrene, methylan-
thracenes/phenanthrenes, fluoranthene,
pyrene, B[a]P, benzo[b]fluoranthene,
benzo[k]fluoranthene, indeno[1,2,3-
cd]pyrene, benzo[ghi]perylene, and coronene
are the most representative PAHs, based on
qualitative and quantitative properties of
emissions and also with regard to their pres-
ence in ambient air (Figure 6). Furthermore,
both particles and gas-phase samples should
be monitored and analyzed. In addition,
dibenzothiophene and benzo[b]naph-
tho[2,1-d]thiophene (Alsberg et al. 1989)
might be useful indicators of fuels contain-
ing sulfur (possibly long-range transport),
and retene might be a marker for wood
burning in regions where softwood is the
dominant fuel. 
Conclusions
The emission estimates regarding PAHs are
generally more uncertain than those for
other pollutants. There might be differences
in the number of PAHs reported and the
sources included in the estimates from vari-
ous countries. In the United States and
Sweden, residential burning of wood is
regarded as the largest source of PAHs.
However, in city centers, mobile sources
(including working machinery) contribute
the major part of the PAH emissions. 
The data on total emissions are uncertain
because some sources have not been
sufficiently well characterized, for example,
wood-fire emissions, many industrial
emissions, and diffuse emissions from prod-
ucts containing asphalt and tar components.
A substantial decrease has occurred in total
PAH emissions in Sweden since 1960.
However, such a decrease cannot be
observed in the measurements of PAHs in
the background air. This discrepancy can be
partly explained by large variations in meteo-
rologic conditions and series measurements
of insufﬁcient duration.
Today, wood burning is believed to be
the major source of PAH emissions to air in
Sweden, with about 60% of total emissions;
trafﬁc contributes about 30%. Older passen-
ger cars without catalytic converters and
older diesel vehicles contribute the greatest
part of the trafﬁc-related emissions of PAHs.
Cold starting for gasoline-driven vehicles is
an important contributing factor for PAH
emissions. 
PAH emission proﬁles are not speciﬁc to
each source but rather reflect efficiency in
combustion and fuel quality in general. In
general, however, diesel is characterized by
PAHs of a lower molecular mass, whereas
wood burning and petrol cars without cat-
alytic converters emit a larger fraction of
heavy multiringed PAHs. Modern diesel
engines using MK1s and modern catalyst-
equipped gasoline cars emit minute amounts
of heavy PAHs such as B[a]P.
Total PAH levels (i.e., the sum of indi-
vidual PAH concentrations determined) of
ambient air from different studies are often
difﬁcult to compare, as both the number of
PAHs analyzed and individual PAH species
may differ. The concentrations of defined
PAHs must therefore be presented before a
comparison can be made. In Europe, B[a]P
concentrations are often below 1 ng/m3 at
background stations, whereas at locations
close to trafﬁc, concentrations range between
1 and 5 ng/m3. 
In the center of Stockholm (Hornsgatan)
the sum of 14 PAHs ranged from 100 to
200 ng/m3. The B[a]P levels were between 1
and 2 ng/m3, which corresponded to 1% of
the total amounts of PAHs measured. The
most abundant PAH was phenanthrene,
which constituted about one-third of the
total amount. In the city of Gothenburg the
median level of particle-bound B[a]P was
0.39 ng/m3 (range 0.12–1.6 ng/m3). The
relative distribution of PAHs in urban back-
ground air in Gothenburg was similar to
that in Stockholm. Because B[a]P is such a
small fraction of the total PAHs, there is a
great need for other health and emission-
relevant PAH markers for comparisons and
evaluation of trends.
In conclusion, PAH compounds selected
for the purposes of monitoring and measur-
ing air pollution were the six so-called
Borneff PAHs (ﬂuoranthene, B[a]P, benzo-
[b]fluoranthene, benzo[k]fluoranthene,
indeno[1,2,3-cd]pyrene, and benzo[ghi]-
perylene), phenanthrene, methylanthracenes/
phenanthrenes, pyrene, and some specialized
markers, namely retene, dibenzothiophene
(PAH-containing sulfur), and benzo[b]naph-
tho[2,1-d]thiophene (PAH-containing sul-
fur). Both particles and gas-phase samples
should be monitored and analyzed.
Mechanistic Aspects of
Biological Activity
Mechanisms of Action of PAHs
The concept of carcinogenesis. Carcinogenesis
is a multistep, multimechanism process
involving genotoxic events (mutations),
altered gene expression at the transcriptional,
translational, and posttranslational levels
(epigenetic events), and altered cell survival
(proliferation and apoptosis) (Hanahan and
Weinberg 2000). Operationally, the carcino-
genic process is often subdivided into three
steps: initiation, promotion, and progression
(Pitot and Dragan 1996).
Tumor initiation encompasses several
distinct requirements, which for chemical
carcinogens include the compound (reactive
per se or reactive following metabolism)
reacting with and thus causing changes in
DNA. In many cases these changes consist
of adducts. Following DNA replication, the
DNA damage caused by these reactive
agents may be fixed as a mutation; such
compounds are therefore called genotoxic. A
mutation in one of a few critical genes in a
cell is considered a key event in the cancer
process. Such mutations include those in
protooncogenes and tumor suppressor genes
involved in signal transduction, DNA
repair, and cell proliferation and differentia-
tion (Kinzler and Vogelstein 1998). Further
development of the mutated or initiated cell
to a tumor depends on the interaction of
the mutation with inherited and acquired
factors that are determinants of growth in
the tissue. Available information indicates
that genotoxic compounds provoke risk
increments that, for low doses, are linearly
dependent on the dose of reactive com-
pound or metabolite, namely, without any
no-effect threshold dose.
As tumor initiation by definition
involves a mutation, this step is in practice
an irreversible process unless the mutated
cell is removed, for instance, by apoptosis.
The genotoxicity of a particular com-
pound may be potentiated in the presence
of cocarcinogens, namely compounds that,
for example, increase the dose by increasing
the rate of bioactivation and/or decreasing
the rate of detoxification of the reactive
intermediates.
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involves the reprogramming of cells toward
propensity for proliferation. This phase can
be interrupted, if not reversed, when expo-
sure to the promoting condition or agent is
stopped. Studies of chemical promoters
reveal that, unlike chemical mutagens, these
compounds do not require interaction with
DNA to exert their action. 
Tumor progression is considered irre-
versible and is characterized by an increased
genomic instability and a further develop-
mental evolution toward malignancy and
autonomous cell growth. 
Certain compounds such as PAHs may
exert both mutagenic (genotoxic) and epige-
netic (nongenotoxic) actions. PAHs with
both initiator and promoter actions are con-
sidered complete carcinogens and may act at
different stages in the carcinogenic process.
The tumor-initiating properties of PAHs
have been studied extensively, whereas the
epigenetic effects of these compounds have
only recently gained interest. Various factors
believed to be of importance in this respect
are discussed below.
Routes of action. The potent biological
activity of PAHs seems to rely on different
characteristic properties. One important
property of PAHs is their metabolic conver-
sion to reactive electrophilic intermediates
that can covalently bind nucleophilic targets
in DNA, RNA, and proteins (Sims and
Grover 1974; Thakker et al. 1985). Thus, in
addition to forming adducts with DNA and
inducing mutations and eventually tumors,
reactive metabolites may react with other
cellular targets and interfere with transcrip-
tion, DNA replication, and protein synthe-
sis. Furthermore, certain PAHs may,
following metabolism, induce inﬂammatory
processes (Casale et al. 1998). A second
important property of certain PAHs is their
high affinity to the cytosolic aryl hydrocar-
bon, or Ah receptor, and the subsequent
transcriptional upregulation of a battery of
genes involved in biotransformation,
growth, and differentiation. The stimulation
of growth seems to be the main component
of promotion in chemical carcinogenesis.
The Ah receptor is a ligand-activated tran-
scription factor that acts in concert with the
Ah receptor nuclear translocator (ARNT) to
alter the expression of target genes such as
cytochrome P4501A1, P4501A2, and
P4501B1, and other biotransformation
enzymes, including glutathione transferases
(GSTs) (Nebert et al.1993; Okey et al.
1994). From recent studies it has become
clear that the Ah receptor belongs to the
bHLH-PAS family of transcriptional regula-
tory proteins, whose members play key roles
in development, circadian rhythmicity, and
environmental homeostasis. Another
property of PAHs is their inhibitory effect
on gap junctional intercellular communica-
tion. It is interesting to note that PAHs con-
taining a bay or a baylike region (see below)
are more inhibitory than PAHs lacking this
structural feature (Upham et al. 1996; Weiss
et al. 1998).
It could be noted that halogen-substituted
polycyclic compounds such as dioxins and
dioxinlike compounds exert biological activity
through nongenotoxic mechanisms, whereas
the carcinogenic potency of PAHs seems to
rely more on genotoxic mechanisms (Harvey
1991; Jerina et al. 1991; Sims and Grover
1974; Thakker et al. 1985).
Structure–activity relationship.
Systematic studies employing different
experimental animal species including rats
and mice have revealed the structural
requirement for PAHs to be mutagenic and
carcinogenic. PAHs composed solely of
fused benzenoid rings (alternant PAHs)
must be composed of at least four rings and
arranged in such a fashion that the molecule
contains a bay or a fjord region (see Figure 7
for definition) (Sims and Grover 1974;
Thakker et al. 1985). Exceptions exist where
the requirements are fulfilled, but the sub-
stances lack or demonstrate very low muta-
genic and carcinogenic activity (see below).
For nonalternant PAHs composed of both
benzenoid and ﬁve-carbon–membered rings
such as ﬂuoranthene and its derivatives, dif-
ferent structural requirements are important
for their action. 
IARC has evaluated the carcinogenicity
of several individual PAHs (IARC 1983,
1987a). As no human data exist for individ-
ual PAHs, the evaluations are based on ani-
mal experiments. The most common
experiments are rodent skin assays, but there
are also intraperitoneal, oral, intrapul-
monary, and intratracheal exposures. Only
B[a]P has been tested by inhalation. The
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Figure 7. Examples of nontumorigenic (A) and documented tumorigenic (B) PAHs. The bay and fjord regions are
indicated by arrows.
(-CH3)
Napthalene Anthracene Phenanthrene
Pyrene
Benzo[e]pyrene
Coronene
Bay region Fjord region
Chrysene Benzo[c]phenanthrene
Benzo[a]pyrene Dibenzo[a,l]pyrene
A
Bevidence that the compound is carcinogenic
to experimental animals is classified by the
IARC as either inadequate (I), limited (L) or
sufﬁcient (S). These classiﬁcations, together
with the overall evaluations concerning car-
cinogenicity to humans, are shown in Tables
10 and 11. In a recent IPCS document
(WHO/IPCS 1998), the carcinogenicity of
33 individual PAHs was reevaluated. These
results are also shown in Tables 10 and 11.
It can be concluded from Tables 1, 10, and
11 that complex mixtures rich in PAHs and
an increased molecular mass of the PAHs,
and thus an increasing number of benzenoid
rings, seem to be associated with an
increased risk for tumor development. 
Structural requirements for genotoxic
action. As previously mentioned, fjord-
region compounds are more active as muta-
gens and carcinogens (Harvey 1991; Jerina
et al. 1991). Figure 7 shows examples of
PAHs that were either noncarcinogenic or
carcinogenic in experimental animals.
Although we are dealing mainly with unsub-
stituted PAHs here, it is interesting to note
that substitutions such as methylation at cer-
tain positions may increase or decrease the
biological potency of a particular PAH. For
instance, methylation of the 5-position in
chrysene (Figure 7) greatly potentiates the
mutagenic and carcinogenic effect, whereas
methylation at other positions may have no
effect or, rather, reduce the potency (Hecht
et al. 1985). The effect of methylation of
phenanthrenes offers another interesting
example. The parent compound (Figure 7)
and all possible monomethyl derivatives lack
tumorigenic activity (LaVoie et al. 1981,
1982). However, certain monomethyl-
phenanthrenes possess mutagenic activity in
human cells in vitro (Barfknecht et al. 1982).
The lack of tumorigenic activity seems to be
related to factors other than metabolic activa-
tion to electrophilic intermediates (Chu et al.
1992; Hoepfner et al. 1987; Ng et al. 1991;
Nordqvist et al. 1981). However, dimethyla-
tion renders phenanthrene tumorigenic
(LaVoie et al. 1982). A systematic study of a
number of methyl-substituted phenanthrene
as tumor initiators in mouse skin has shown
that 1,4- and 4,10-dimethylphenanthrene are
active, in particular the former (LaVoie et al.
1982). This and other studies indicate that
the activity requires inhibition of dihydrodiol
formation at the 9,10 position to block
detoxiﬁcation, in addition to a methyl group
and a free peri position adjacent to the
unsubstituted angular ring. For further infor-
mation on effects of methylation of various
PAHs, consult Hecht et al. (1985).
Structural requirements for promoter
action. For a promotive action of PAHs,
interaction with the Ah receptor or some
similar receptor seems to be one essential
mechanism (Poland et al. 1982). This would
mean that in this case the promoter action is
exerted by the parent hydrocarbons, i.e.,
species different from the mutagenic diol
epoxide (DE) (see “Metabolism”). The Ah
receptor is postulated to play a role in nor-
mal growth and development based upon
patterns of Ah receptor expression during
the early development of mouse and human
embryos (Abbott et al. 1994; Peters and
Wiley 1995). The receptor is widely
expressed, but a physiologic ligand has not
yet been convincingly shown. Indications
that endogenous Ah receptor ligands may be
derived from the amino acid tryptophan
have repeatedly been reported (Helferich
and Denison 1991; Perdew and Babbs 1991;
Rannug et al. 1987). Derivatives of trypto-
phan with an indolo[3,2-b]carbazole skele-
ton have been found to possess very strong
afﬁnity for binding to the receptor, suggest-
ing that they are the endogenous ligands
(Rannug et al. 1987, 1995).
Inappropriate activation of the Ah receptor
by aromatic hydrocarbons induces a variety
of biological effects. These include increased
proliferation, inhibition of differentiation as
well as endocrine disruption, and tumor pro-
motion in experimental animals. The mech-
anisms for Ah receptor-mediated tumor
promotion can involve genes transcribed
simultaneously with cytochrome P450 genes
(Nebert et al. 1993) or result from the acti-
vation of tyrosine kinase activity and subse-
quent phosphorylation of growth factors and
hormones (Enan and Matsumura 1996). 
To possess strong Ah receptor binding
affinity, the molecules must fit into a rec-
tangle with the approximate size of 6.8 ×
13.7 Å (Gillner et al. 1985). Another
important structural requirement for Ah
receptor binding is the presence of sub-
structures such as the bay region that are
also linked to metabolism. This indicates
strong similarities between the PAH recog-
nition site of the Ah receptor and the active
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Table 10. The degree of evidence for carcinogenicity of alternant PAHs in experimental animals, and
overall evaluations of carcinogenicity to humans.a
IARC
PAH compound Number of rings Animals Humans  WHO
Anthracene 3 I 3 – 
Phenanthrene 3 I 3 (+/–)
Benzo[c]phenanthrene 4 I 3 (+/–)
Chrysene 4 L 3 +
Benz[a]anthracene 4 S 2A +
Pyrene 4 I 3 (+/–)
Triphenylene 4 I 3 (–)
B[a]P 5 S 2A +
Benzo[e]pyrene 5 I 3 +/–
Dibenz[a,c]anthracene 5 L 3
Dibenz[a,h]anthracene 5 S 2A +
Dibenz[a,j]anthracene 5 L 3
Perylene 5 I 3 (–)
Anthanthreneb 6L 3+
Benzo[ghi]perylene 6 I 3 –
Coronenea 6 I 3 (+/–)
Dibenzo[a,e]pyreneb 6S2 B +
Dibenzo[a,h]pyreneb 6S2 B +
Dibenzo[a,i]pyreneb 6S2 B +
Dibenzo[a,l]pyreneb 6S2 B +
Abbreviations: I, inadequate evidence; L, limited evidence; S, sufﬁcient evidence; 2A, probably carcinogenic to humans;
2B, possibly carcinogenic to humans; 3, not classiﬁable; –, negative; +, positive; +/–: questionable; ( ), limited number of
studies. aEvaluated by IARC (1983, 1987a) and WHO/IPCS (1998). bFor nomenclature according to the IUPAC system, see
the Appendix. 
Table 11. The degree of evidence for carcinogenicity of nonalternant PAHs in experimental animals, and
overall evaluations of carcinogenicity to humans.a
IARC
PAH compound Number of rings Animals Humans  WHO
Fluoranthene 4 I 3 (+)
Benzo[b]ﬂuorantheneb 5S2 B +
Benzo[j]ﬂuoranthene 5 S 2B +
Benzo[k]ﬂuoranthene 5 S 2B +
Benzo[ghi]ﬂuoranthene 5 I 3 (–)
Cyclopenta[cd]pyrene 5 L 3 +
Dibenzo[a,e]ﬂuoranthene 6 L 3
Indeno[1,2,3-cd]pyrene 6 S 2B +
Abbreviations: see Table 10. aEvaluated by IARC (1983, 1987a) and WHO/IPCS (1998). bFor nomenclature according to the
IUPAC system, see the Appendix.site of the cytochrome P450 enzymes
(Rannug et al. 1991). 
The ability of PAHs to act as promoters
very strongly increases their carcinogenic
potency, as shown at the high doses that are
administered in animal cancer tests. It is
therefore expected that a multifactorial
analysis of a number of bay-region PAHs
shows Ah receptor affinity to be a much
stronger predictor of carcinogenicity than
the mutagenic potency (Sjögren et al. 1996).
This general view is also reﬂected in the car-
cinogenicity evaluation of the IARC: Those
PAHs that are considered carcinogenic have
mainly high Ah receptor afﬁnity, and those
judged to be noncarcinogenic have no or low
afﬁnity to this receptor. It should be empha-
sized that this conclusion is restricted to the
planar bay-region PAHs and may not reﬂect
the very high mutagenic/carcinogenic
potency of the fjord-region PAHs. Available
information indicates that the latter are
strong mutagens and carcinogens (Harvey et
al. 1991; Jerina et al. 1991), despite their
lower affinity to bind to the Ah receptor
(Ionanides and Parke 1990, 1993), and
induce their own metabolism to yield DEs
through a non-Ah receptor–mediated mech-
anism (see below). In addition to promoting
the carcinogenic process by interacting with
the Ah receptor, PAHs may amplify the
tumor promotion process via alternative
mechanisms such as induction of inﬂamma-
tory processes and stimulated oxidative stress
(Casale et al. 1998).
Metabolism. PAHs are highly lipophilic
compounds of low chemical reactivity and
have to be metabolically activated to elec-
trophilic intermediates (a species with an
absolute positive or a relative positive
charge). The metabolism of PAHs has been
studied using cells and cell fractions derived
from both animal and human tissues, and it
is exceedingly complex (Cooper et al. 1983;
Gelboin 1980; Sims and Grover 1974;
Thakker et al. 1985). In general, biotransfor-
mation of xenobiotics involves a number of
enzymes, some of which are localized in the
endoplasmic reticulum and others in the
nuclear envelope, mitochondria, and cytosol.
The metabolism of xenobiotics is usually
divided into three phases: phase 1 leads to
the formation of electrophilic intermediates,
phase 2 most often leads to deactivation of
reactive electrophiles by various conjugation
reactions, and phase 3 is the active transport
of polar metabolites from the cell into the
surrounding environment. With respect to
PAHs, alternative phase 1 activation path-
ways have been identiﬁed. One leads to the
formation of various epoxides, and one
involves one-electron oxidation to yield radi-
cal cation intermediates (Cavalieri and
Rogan 1995). The electrophiles formed
undergo phase 2 reactions to phenols,
diones, dihydrodiols, and more polar and
excretable metabolites such as glucuronides
and conjugates with sulfate or glutathione
(Cooper et al. 1983; Gelboin 1980; Sims
and Grover 1974; Thakker et al. 1985). 
It has been shown for various PAHs that
the radical cations formed by the one-electron
oxidation pathway give rise to labile DNA
adducts that readily decompose by depurina-
tion (Cavalieri and Rogan 1995), whereas the
epoxide pathway preferentially leads to the
formation of stable adducts (see below). 
Extensive studies of mutagenic and car-
cinogenic PAHs and their metabolites have
identified so-called bay- and fjord-region
DEs as ultimate reactive species (Harvey
1991; Jerina et al. 1991). The formation of
DEs is a three-step process and it will be
described for B[a]P. It should be emphasized
that what is described for B[a]P regarding
metabolic transformation can be applied to
many alternant PAHs. As shown in Figure 8,
the first step in the metabolism of B[a]P
results in the formation of BP-7,8-epoxide
(the isomer preferentially formed is
depicted). This step is mainly catalyzed by
the cytochrome P450 isoenzyme CYP1A1.
The second step is catalyzed by epoxide
hydrolase (EH) and yields a trans-dihydro-
diol (BP-7,8-dihydrodiol). The last step
involves a second epoxidation at the 9,10
position, and results in the formation of diol
epoxide diastereomers, syn-benzo[a]pyrene
7,8-dihydrodiol 9,10 epoxide (syn-BPDE)
(the hydroxyl groups and the epoxide are
localized on the same side of the molecule)
and anti-BPDE (the hydroxyl groups and
the epoxide are localized on opposite side of
the molecule), respectively. Each diastere-
omer may in turn exist as a pair of enan-
tiomers, or mirror images of each other [(+)-
and (–)-syn-DE in Figure 8, respectively].
This step may be carried out by CYP1A1,
peroxidase-catalyzed epoxidation, or through
cooxidation by simultaneous exposure to
B[a]P and sulfur or nitrogen oxides
(Cavalieri and Rogan 1995; Constantin et al.
1994; Petruska et al. 1992; Thakker et al.
1985). In addition to CYP1A1, cytochrome
P450 isoenzymes such as CYP1A2,
CYP1B1, and CYP3A4 may also participate
in the metabolic activation of PAHs
(Guengerich 1993; Kim et al. 1998; Nelson
et al. 1996). This seems to be of particular
importance with respect to the metabolic
activation of fjord-region PAHs. With these
compounds CYP1B1 seems to be of major
importance (Einolf et al. 1997; Luch et al.
1998). It should be emphasized that cells
from different human organs contain the
enzymes and enzyme systems required for
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Figure 8. The metabolic activation route of B[a]P to anti- and syn-DEs. The two possible enantiomers (mirror images) of each diastereomer are shown in brackets. 
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In humans a substantial variability in
biological response to PAHs is to be
expected because of interindividual differ-
ences in the activity of the enzyme systems
required for the formation of reactive inter-
mediates and for their detoxiﬁcation through
conjugation and excretion. The enzymes
involved in the metabolism are inducible by
different classes of xenobiotics (e.g., drugs,
environmental factors), and different forms
of metabolizing enzymes (polymorphic vari-
ants) are also found in the population that
may vary in reactivity toward PAHs (see
“Individual susceptibility”).
Requirements for diol epoxide-induced
genotoxicity. Diol epoxide structure. All
possible bay-region DEs from a number of
PAHs have been investigated in different
bacterial and mammalian cell systems and in
experimental animals (primarily mice but
also rats) with regard to mutagenic and car-
cinogenic potency. In studies using mice, the
compounds are usually administered by skin
painting to adult animals but are also admin-
istered orally or by subcutaneous injection to
newborn animals. Female rats have been
used for mammary carcinogenicity studies
after injection of PAHs under the nipples.
Taken together, the DEs associated with
high biological activity in mammalian sys-
tems are in general the anti-diastereomers
and, in particular, the enantiomers with
R-absolute configuration at the benzylic
arene carbon (Glatt et al. 1991; Thakker et
al. 1985); in BPDEs, this position corre-
sponds to C-10 (Figure 8). In contrast, bac-
terial systems respond differently, and
experiments with BPDEs suggest that anti-
enantiomers with S-absolute configuration
are usually more mutagenic (Figure 8)
(Burgess et al. 1985). The reason for the dif-
ferent response in mammalian versus bacter-
ial cells is not known. However, the
phenomenon may be related to the different
structures of the DNA adducts derived from
DE isomers with R- or S-absolute conﬁgura-
tion (see “DNA adducts” below) and how
these adducts are recognized and handled by
the enzyme systems participating in DNA
repair and replication. Certain implications
in the risk assessment of PAHs are obvious
using bacterial systems, as the results may
falsely identify less-relevant derivatives as the
most active forms.
With the fjord-region DEs, the situation
seems to be more complex with respect to
the structure–effect relationship. Although
these compounds are in general less chemi-
cally reactive than the bay-region DEs, they
are in many cases considerably more muta-
genic and carcinogenic (Glatt et al. 1991;
Wood et al. 1984). In contrast to most
bay-region DEs, both the anti- and
syn-diastereomers of the fjord-region deriva-
tives demonstrate high mutagenic and
tumorigenic activity (Amin et al. 1995;
Higginbotham et al. 1993; Levin et al. 1986;
Nesnow et al. 1997).
DNA adducts. Detailed studies have
been conducted on the interaction of DEs
with DNA both in vitro and in vivo
(Geacintov et al. 1997; Gräslund and
Jernström 1989; Jeffrey 1985; Jerina et al.
1991). It has been shown that DEs demon-
strate a high preference for the exocyclic
amino groups of deoxyguanosine (dG) and
deoxyadenosine (dA) (Figure 9). Unless
removed by DNA repair processes, the
resulting adducts may give rise to mutations
following DNA replication. In mammalian
cells, exposure to stereochemically different
DEs results in mutations that differ in num-
ber, type (base substitutions such as transver-
sions and transitions, deletion of one or
several bases, etc.), and sequence context dis-
tribution (Jernström and Gräslund 1994).
The heterogeneous distribution of mutations
is the combined result of the initial adduct
distribution and adduct removal by DNA
repair processes. Recent results have shown
that adduct recognition and the rate of
adduct removal depend on the bases sur-
rounding the adducted base (Hess et al.
1997; Wei et al. 1993, 1994).
The great majority of DE-induced
mutations in cells are localized in the
nontranscribed strand of DNA. The main
reason for this phenomenon is that the exci-
sion repair system responsible for recogni-
tion and handling of DNA adducts
preferentially eliminates lesions localized in
the coding strand (Jernström and Gräslund
1994; Mellon et al. 1987). 
Transversion mutations (GC→TA or
AT→TA) are most prevalent in mammalian
cells after DE exposure. It is interesting to
note that the p53 tumor suppressor gene is
frequently mutated in different human can-
cers and that the types of mutation and
base(s) involved differ depending on the
causative agent. Thus, tumors believed to be
caused by PAHs show critical transversion
mutations (GC→TA or AT→TA) in the
p53 gene, whereas alkylators like nitroso
amines or amides show transitions derived
from alkyl-dG adducts (Harris 1991;
Holstein et al. 1991). A recent study has
shown that mutational hot spots in the p53
gene coincide with codons demonstrating a
preference for adduct formation with DEs
from B[a]P (Denissenko et al. 1996; Smith
et al. 2000). It can be concluded that differ-
ent DEs vary in their preference for dG or
dA, the preference being dependent on the
bases adjacent to the target base and because
DEs with higher mutagenic and carcino-
genic potency induce a different pattern of
mutations than less-active DEs. Studies
employing oligonucleotides with known
base composition have clearly shown that
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Figure 9. The principal targets in DNA for adduct formation with DEs. Alternative reaction routes exist: cis-addition,
in which the adducted base is located on the same side of the DE molecule as the adjacent hydroxyl group, and
trans-addition, in which the same groups are located on the opposite side of the DE molecule. R and S denote the
absolute structure of the DE stereoisomers shown.
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N 2-dG (N 6-dA)whether the covalent binding of DEs
involves dG or dA and to what extent this
occurs greatly depends on both bases being
adjacent to the target base and on stereo-
chemical features of the DEs (Geacintov
et al. 1997; Jernström and Gräslund 1994).
Much is known about the structure of the
DNA–DE adducts (Geacintov et al. 1997;
Gräslund and Jernström 1989; Jerina et al.
1991). The reaction of a DE with the exo-
cyclic amino group of dG or dA can proceed
through trans or cis addition of the nitrogen
to the benzylic carbon of the arene oxide.
Figure 9 shows the alternative reaction path-
ways. The trans addition pathway dominates.
At present only limited information exists on
the relationship between adduct structure and
the type of mutation induced in mammalian
systems. In other words, it is not known
whether trans adducts are more mutagenic
than the corresponding cis adducts. These
interesting and important problems are
presently being intensively studied.
The greater biological activity usually
observed with fjord-region DEs relative to
the bay-region analogs may be due to the
higher preference of the former for reacting
with dA. A contribution to the difference
may be that the syn-diastereomers of fjord-
region-DEs are active in contrast to those
derived from the bay-region DEs. The rea-
son may be that the hydroxyl groups in the
sterically hindered fjord-region DEs remain
in a pseudodiequatorial position, which is
not the case in the weakly active syn-diastere-
omers of the bay-region DEs (Figure 10).
The importance of the spatial orientation of
the hydroxyl groups for the biological activ-
ity has been shown experimentally (Chang
et al. 1987). The crowdedness in the fjord-
region renders these compounds nonplanar
in contrast to the planar bay-region DEs.
Biologically active PAHs composed of
both fused benzenoid and ﬁve-member rings
such as ﬂuoranthene and its derivatives along
with cyclopenta[c,d]pyrene (Figure 11), may
be activated through alternative pathways.
One pathway results in the formation of
classical bay- and fjord-region DE interme-
diates, whereas the other gives rise to a DE
in which the ﬁnal epoxidation involves a car-
bon in the cyclopentyl residue (Keohavong
et al. 1995; Phillips and Grover 1994). The
available data indicate that the classical DEs
are the most active. To further complicate
the picture, activation of certain derivatives
of ﬂuoranthene (i.e., benzo[b]ﬂuoranthene)
requires, in addition to the formation of a
DE, aromatic hydroxylation, and thus an
intermediate formation of a triol epoxide
(Mass et al. 1996).
Dose–response relationships for carcino-
genicity. The very high tumor incidences
observed in rodent cancer tests of PAHs have
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relevant to the cancer risk at the mostly low
levels of PAHs in human exposures. It is rec-
ognized that several PAHs are complete car-
cinogens, namely, they are able to cause both
initiation (mutation) and promotion (stimu-
lation of clonal expansion and growth). The
dose–response relationships of PAH-induced
cancer in animal experiments are mostly
nonlinear, with an upward rise at high doses
(Ehrenberg and Scalia-Tomba 1991). This is
in agreement with the idea that promotion is
a nonstochastic (deterministic) effect, with
an S-shaped dose–response curve above a
no-effect threshold. This is in contrast to
purely genotoxic carcinogens, which elicit
tumors in linear dose–response relationships.
These tumors appear at sites where inherited
or acquired promotive conditions occur,
namely, where tumors occur in the unexposed
control (Granath et al. 1999). This gives
some support to the suggestion that com-
pared with other mathematic models, a mul-
tiplicative model for cancer incidence, Pcan, is
the one best adaptable to experimental data
for PAH carcinogenesis.
Pcan = Pini × Ppro
In this approach, the probability of initi-
ation, Pini, is modeled by a linear, non-
thresholded curve, and the probability (and
intensity) of promotion Ppro by the S-shaped
cumulative probability function (Ehrenberg
and Scalia-Tomba 1991). Furthermore, the
thresholded, S-shaped dose response for skin
tumors induced by B[a]P becomes linearized
if an effective nonmutagenic promoter, 12-
O-tetradecanoylphorbol-13-acetate) (TPA),
is added (Burns et al. 1983) (Figure 12A).
This general picture is important to the risk
estimation for PAHs at low exposure levels.
The risk (probability) of cancer at low
doses of a genotoxic agent at the present
level of knowledge has been assumed to be
linearly dependent on the dose without a
threshold (Ehrenberg 1998; Törnqvist and
Ehrenberg 2001). The cancer-initiating abil-
ity of a purely genotoxic agent, according to
the expression above, could only be
expressed in animal tests if a background
promotion (P 0
pro) is present. If little or no
background promotion exists, the cancer-
initiating ability will be expressed at high
doses only when and if the tested com-
pound, through different mechanisms, can
act as a promoter. In this case, a threshold or
a no-effect level will be observed. If the
tested compound acts as an efficient pro-
moter, the dose–response relationship will
deviate from linearity.
According to this model it is assumed
that because of the ubiquitous occurrence of
background mutations, promoters will lead
to a raised cancer risk above some threshold
dose. When the mechanism is epigenetic,
the dose–response relationship is expected
to be S-shaped with a no-effect threshold.
However, if a compound is added to other
compounds acting by the same mechanism
and already present at levels exceeding the
threshold, it will increase the risk in a lin-
ear, nonthreshold dose dependence (Crump
et al. 1976) (Figure 12B). For PAHs acting
by interaction with the Ah receptor, this
may happen if there is simultaneous expo-
sure to certain planar PCBs, chlorinated
dibenzo-p-dioxins, and dibenzofurans
(Ahlborg et al. 1994).
If the cytochromes P450 required for
bioactivation of PAHs are already expressed,
the initiating (mutagenic) action of the DE
will be of major importance to the risk at the
lower levels below the threshold for P450
induction (this threshold is probably approx-
imately the same for the concomitant pro-
moter action). Induction of the P450
enzymes responsible for DE formation, at
least from certain bay-region PAHs (Luch
et al. 1998), is exerted by the interaction of
the PAHs with the Ah receptor. The ensuing
increase of the rate of DE formation may
contribute to the rise of the dose–response
curves at higher doses. Because both promo-
tion and increased DE production lead to
the same upward bend of the dose–response
curves, it is difﬁcult to identify the operating
mechanism without measurement of the
in vivo dose of the DE.
Comments on indicator compounds.
A central point in the present discussion of
cancer risk at low-exposure levels of PAHs
and the selection of indicator compounds is
whether we should accept a qualitative para-
digm based on animal experiments at high
exposure levels that will never occur in the
human environment. A mutagenic com-
pound not acting as a promoter may, on the
basis of a negative animal cancer test, be
classiﬁed as a noncarcinogen. However, such
a compound is expected to interact with
inherited and acquired promotive conditions,
increasing the incidence of the kinds of
tumors that already occur at low levels in the
unexposed control population (Granath et al.
1999; Törnqvist and Ehrenberg 2001). There
are PAHs that are metabolized to effective
mutagens but lack strong tumor-promoting
activity and could therefore be expected to
belong to this group of compounds.
One example of a PAH as possible
important risk factor, although it has previ-
ously been classified as a noncarcinogen
(IARC 1987b), is fluoranthene. This com-
pound is interesting because of its occur-
rence at relatively high concentrations in
vehicle emissions and other types of emis-
sions of PAHs, in ambient air (see “Sources,
Deposition, and Ambient Concentrations”
and WHO/IPCS 1998), inside vehicles
(Fromme et al. 1998), and also because the
dietary intake of PAHs comprises relatively
large amounts of fluoranthene compared
with other measured PAHs (reviewed in
WHO/IPCS 1998). 
Fluoranthene, like B[a]P, is metabolized
to mutagenic DEs and its mutagenic
potency is close to that of B[a]P (Vaca et al.
1992). The carcinogenic action of fluoran-
thene diolepoxide has been demonstrated
experimentally (Amin et al. 1995; Hecht et
al. 1995). In carcinogenicity tests with high
doses, however, B[a]P is considerably more
effective than fluoranthene (Busby et al.
1984), evidently because of the promoter
action of B[a]P (Vaca et al. 1992). Although
ﬂuoranthene is now considered a weak car-
cinogen (WHO/IPCS 1998), the observed
cancer incidence and the numbers of tumors
per animal are compatible with linear dose–
response relationships (Wang and Busby
1993). Therefore, at low exposure levels, at
which induced mutation is a determinant of
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Figure 12. With higher doses of B[a]P, when it acts as both initiator and promotor, skin tumors are induced in mice
(thresholded curve). If the B[a]P treatment is combined with a promotor treatment (TPA), B[a]P initiates tumors with a
linear dependence on dose (A). Hypothetical dose–response curve for the action of a promoter operating in the
absence or presence of another promoter that operates by the same mechanism and that has exceeded the no-effect
threshold (B). P(D) denotes risk for health effects; P0 denotes background frequency.
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because of its abundance in the environ-
ment, might be an important contributor to
the risk from PAH exposure (Barfknecht et
al. 1982; Sjögren et al. 1996). 
Whereas the bioactivation of B[a]P by
CYP1A enzymes is well documented, the
metabolism of ﬂuoranthene has not yet been
clarified. It has been shown, however, that
fluoranthene is metabolized to the corre-
sponding DEs by human liver microsomes
(Day et al. 1992). 
PAH Exposure in Humans
Routes of exposure. Humans can be exposed
to PAHs a) through the respiratory tract by
inhalation of PAH-containing matter such as
cigarette smoke, vehicle exhaust, PAH-
contaminated air emitted from certain indus-
tries or by the burning of wood for heating,
etc., b) through the digestive tract following
intake of PAH-containing foodstuffs (e.g.,
fried and charcoal-grilled meat) and PAH-
contaminated vegetables and crops grown
close to areas with intense trafﬁc, etc., and c)
through the skin following contact with sub-
stances such as petroleum products (e.g., soot,
pitch, and tars). Several organs are believed to
be susceptible to tumor formation after expo-
sure to PAHs (Doll et al. 1994; IARC 1983,
1987a,b; U.S. PHS 1979). These include the
lungs (in particular the bronchi), the skin, the
esophagus and colon, the pancreas, the
bladder, and the breast in women.
In an earlier study on the cancer risk
from urban air pollutants, uptake via food
of precipitated particulate material on
crops, etc., has been discussed as a possible
major source of PAH uptake (Törnqvist
and Ehrenberg 1994). Several studies have
indeed shown that the intake of PAHs via
the diet is large (Beckman Sundh et al.
1998; de Vos et al. 1990) and much higher
than the intake via inhalation (Lioy et al.
1988; Lodovici et al. 1995; Vaessen et al.
1988; WHO/IPCS 1998). Data on the ori-
gin of PAHs in food are limited; however,
it has been suggested that the major part
originates from precipitated particulate
material (de Vos et al. 1990; Lodovici et al.
1995). In fact, it has been demonstrated
that the PAH content is higher in products
from crops cultivated near roads and cities
(Larsson 1986). The relatively high back-
ground levels of PAH adducts to both pro-
tein and DNA observed in nonsmokers
(see below, “Biomarkers of exposure”)
indicate that the diet might be quantita-
tively the most important source of PAHs.
Furthermore, it has been shown in mice
that oral intake (or by gavage) of B[a]P gives
approximately the same dose of BPDE in
the lung as in other organs (Godschalk et al.
2000; Helleberg et al. 2001). However, the
relative contributions to the total PAH
exposure from different sources and, more
important, to the internal dose of PAHs, are
still very uncertain.
Biomarkers of exposure. Biomonitoring of
exposure to PAHs has been extensively
reviewed by Angerer et al. (1997). The meth-
ods used—DNA adduct and protein adduct
measurement and the measurement of urine
metabolites—are discussed regarding analytic
techniques and usefulness, and studies of
exposed populations are discussed with regard
to results obtained in relation to exposure
measurements. A drawback with the methods
used for DNA adduct measurement, accord-
ing to the authors, is the nonspeciﬁcity of the
detection, although this could be partly coun-
teracted by the use of the high-performance
liquid chromatography (HPLC) methods
now being developed for the separation of
DNA adducts (Hemminki et al. 1997; Zeisig
and Möller 1997; Tuominen et al. 2002).
The analysis of protein adducts and urine
metabolites is favorable with regard to the
speciﬁcity of detection when mass spectrome-
try is used. According to Angerer et al.
(1997), analysis of urine metabolites is the
procedure for assessment of PH exposure
which has so far given the most clear-cut
results. A drawback with this method is the
difficulty in drawing conclusions about the
in vivo dose of the reactive metabolites.
DNA adducts. As mentioned previously,
the enzymatic activities required for the
metabolic transformation of PAHs to DEs
exist in human tissues. Experiments with
human cells or tissues in culture have clearly
demonstrated that DEs formed bind cova-
lently to DNA. Several studies have been
performed to identify and quantify the DNA
adducts in human tissues following exposure
to PAH-containing material in, for example,
cigarette smoke, urban air, and contami-
nated workplaces. Several methods for
adduct analysis have been developed, includ-
ing antibodies against speciﬁc PAH adducts
(e.g., enzyme-linked immunosorbent assay
[ELISA]), fluorescence spectroscopy, mass
spectrometry, and 32P-postlabeling of modi-
fied nucleotides (Phillips 1996). All the
methods have advantages and disadvantages.
The first three methods can in principle be
used for both identification of specific
adducts and quantification, but they often
lack the required sensitivity for practical use
in molecular epidemiologic studies.
However, fluorescence spectroscopy has
been successively employed for the detection
of DNA adducts derived from B[a]P in indi-
viduals exposed to PAHs (Rojas et al. 1994,
1998). In human monitoring, peripheral
blood cells such as leukocytes and
lymphocytes are most frequently used as the
source of DNA, but biopsies from target
tissues have also been studied. The
32P-postlabeling technique possesses the
required sensitivity (1 adduct per 107–109
nucleotides) but yields little information
on adduct identity. This method, in con-
junction with thin-layer chromatography
(TLC) of labeled adducts, has been used in
a number of studies. It has revealed that
the extent of adduct formation in human
tissues most often varies by a factor of
about 20, although a variation by a factor
of more than 70 has been observed (Perera
et al. 1992). A recent study indicates that
the adduct levels in humans estimated by
TLC poorly reflect the true levels. The
recovery of labeled adducts with TLC was
only a few percent (5%) relative to the
recovery with HPLC (Hemminki et al.
1997). Furthermore, the resolution of radioac-
tive material is dramatically increased with
HPLC relative to TLC, and at least 50 differ-
ent DNA adducts in the general Swedish pop-
ulation have been detected (Möller 2001).
However, information on their identities is
lacking. Because the 32P-postlabeling tech-
nique involves chromatography, TLC, or
HPLC, the results obtained can be compared
with authentic standards to obtain informa-
tion on adduct identity.
The method with the greatest potential
for identifying the structure of a DNA
adduct is mass spectroscopy, and a number
of adducts have been characterized
(Sweetman et al. 1998). However, the wider
application of the method in human bio-
monitoring has been hindered by insuffi-
cient amounts of DNA from individuals
exposed to environmental contaminants
(Phillips et al. 1996). The methodology is
developing rapidly and further application is
anticipated.
It should also be noted that in most cases
the formation of assumed PAH adducts in
humans has been studied in blood cells,
which reflect the systemic concentration of
the parent compound and/or reactive
metabolites. In a few studies, however, a pos-
itive and exposure-related correlation
between biomarkers in the lung or larynx
and in peripheral blood cells has been
observed (Szyfter et al. 1994; Tang et al.
1995; Wiencke et al. 1995). The results
demonstrated by Wiencke et al. (1995) in
particular emphasize the potential use of
blood cells as surrogates for estimating the
burden of DNA adducts in the lung. In
these studies, the adducts were measured in
lung tissue and blood mononuclear cells
from the same individuals, thereby reducing
the influence from interindividual differ-
ences in susceptibility. High local concentra-
tions of inhaled PAHs retained in the
bronchial epithelium may, however, lead to
higher DNA adduct levels at that site, which
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circulating blood cells (see “Site of formation
of DNA-binding intermediates”).
The results obtained thus far on the rela-
tionship between the exposure of humans to
complex mixtures containing PAHs and the
extent of DNA adduct formation indicate a
correlation, although weak in most cases
(Phillips 1996). This is particularly surpris-
ing in individuals such as heavy smokers, in
which substantially increased adduct levels
were anticipated relative to that in nonsmok-
ers. The apparent lack of, or minor effect of,
smoking on adduct formation is probably
due to the extensive exposure of individuals
to PAHs through other routes (e.g. the
digestive tract) and, accordingly, high basal
levels of adducts in most tissues, including
the lung (Beckman Sundh et al. 1998;
WHO/IPCS 1998). 
The adducts identiﬁed after PAH expo-
sure have been classified as aromatic or
lipophilic, and only in a very few cases have
the adducts been identified (Phillips 1996;
Rojas et al. 1998). 
Protein adducts. Protein adducts of PAH
DEs have been measured in hemoglobin
(Hb) and serum albumin (SA) with different
methods in several studies of occupational
exposure, e.g., in foundry workers (Ferreira
et al. 1994; Sherson et al. 1994; Tas et al.
1994) and in humans with occupational
exposure to automobile exhaust (e.g.,
Hemminki et al. 1994; Pastorelli et al. 1996).
Adducts have been detached from the protein
by mild hydrolysis and analyzed by HPLC
and ﬂuorescence detection, by ELISA, or by
gas chromatography/mass spectrometry
(GC/MS). Background levels in control per-
sons and signiﬁcant increases in adduct levels
in occupationally exposed persons have been
found. Analysis by GC/MS has the highest
speciﬁcity and also allows structural identiﬁ-
cation of the adduct. Adducts from B[a]P
were specifically determined by GC/MS as
B[a]P tetrahydrotetrols in studies of persons
with occupational exposure to trafﬁc exhaust,
with a significant increase in exposed non-
smokers (Pastorelli et al. 1996). A hydrolyz-
able adduct from (+)-anti-BPDE binds to
carboxyl oxygen in aspartate in human Hb
(Skipper et al. 1989).
One drawback with these hydrolyzable
adducts to carboxyl oxygen is their sensitivity
to hydrolysis (and the ensuing fact that they
are not completely stable) in vivo, particularly
in Hb from rat and mouse (Naylor et al.
1990; Viau et al. 1993). Thus, these adducts
are suitable as exposure markers but cannot
be used for the calculation of doses in vivo of
DEs from accumulated adduct levels. 
To overcome this problem of in vivo
instability of adducts, suitable amino or
sulfur adducts from DEs in Hb and SA have
been studied. In human SA, histidine and
lysine adducts have been found after in vitro
treatment with several DEs, among others
from B[a]P and fluoranthene (Brunmark
et al. 1997). After in vitro treatment of
human SA and human Hb with BPDE, a
large fraction of the BPDE adducts is bound
to histidine (Helleberg and Törnqvist 2000).
Recently, a very sensitive method was pub-
lished based on measurement of BPDE-his-
tidine adducts in human SA and measured
with high sensitivity by laser-induced fluo-
rescence as dipeptides after enzymatic diges-
tion (Özbal et al. 2000). With this method a
background adduct level of about 150 fmol
per g SA histidine adduct was measured in
humans. In parallel work a liquid chro-
matography–mass spectrometry method was
developed for measurement of histidine
adducts from BPDE after hydrazinolysis of
the protein (Helleberg and Törnqvist 2000).
Studies in mice after intraperitoneal injec-
tions of B[a]P have shown that histidine
adducts from BPDE are formed much faster
in SA than in Hb (Helleberg 2001).
Urinary PAH biomarkers. Pyrene is a
regular constituent in mixtures containing
B[a]P and other carcinogenic PAHs. The
highly fluorescent pyrene metabolite
1-hydroxypyrene (1-OHP) can be quanti-
fied in urine by HPLC. As a biomarker of
PAH exposure, 1-OHP has gained a strong
position (Angerer et al. 1997; Jongeneelen
1997; Levin 1995). Particulate pyrene is
well correlated with the total PAHs in
breathing zone air samples and 1-OHP in
urine gives a more accurate assessment of
the total PAH exposure from all exposure
routes, including dermal absorption, than
the PAH levels in air. Urinary 1-OHP may
also reﬂect interindividual variation in PAH
metabolism. Pyrene is metabolized by
CYP1A1 and possibly by CYP1B1 (Elovaara
et al. 1995) to 1-OHP, and is excreted in
the urine as the corresponding glucuronide.
CYP1B1 may be particularly important in
the metabolism of pyrene in the human
liver, as the activity has not been found to
be inhibited by CYP1A1/2 antibodies
(Elovaara et al. 1995). 
Most people in Sweden have detectable
amounts of 1-OHP in the urine (Levin
et al. 1986). Background levels of 1-OHP
are normally low, but an influence from
environmental PAH contamination and
smoking can be detected. Median 1-OHP
values of 0.03 and 0.09 µmol/mol creati-
nine have been reported in Swedish non-
smokers and smokers, respectively (Levin et
al. 1986). In occupational settings the 1-
OHP content in urine may be increased by
a factor of 10–100. Coke ovens, carbon
electrode production plants, tar distillation
plants, aluminum smelters, and creosote
impregnation plants represent workplaces
where high urinary 1-OHP levels are often
observed. In a recent biomonitoring study
of a Söderberg aluminum reduction plant in
Sweden, urine samples from 96 pot-room
workers and 5 control subjects were ana-
lyzed for 1-OHP (Carstensen et al. 1999).
Values observed (median, range) were 4.31
(0.09–17.7) µmol/mol creatinine for work-
ers and 0.13 (0.06–0.75) µmol/mol creati-
nine for controls. Canadian residents living
less than 500 m from a Söderberg alu-
minum reduction plant had significantly
increased excretion of 1-OHP compared
with controls living in another industrial
town (Gilbert and Viau 1997).
Urinary metabolites of phenanthrene
(dihydrodiols and phenols) can also be
used for monitoring human exposure to
PAHs. However, this system seems to be
less suitable for monitoring the extent of
exposure and may rather provide informa-
tion on the cytochromes P450 participat-
ing in the metabolism. For instance,
smokers and nonsmokers demonstrate dif-
ferent distribution of phenanthrene
metabolites (Jacob et al. 1999). 
The HPLC-based procedure is relatively
simple and has been further developed to
analyze phenanthrene metabolites (Jacob
et al. 1999; Lintelmann et al. 1994). It is
now possible to determine levels of 1-OHP
in addition to the metabolites of phenan-
threnes down to the nanogram per liter
range, which allows estimation of the PAH
exposures of the general population
(Angerer et al. 1997). In summary, the
HPLC procedure is sensitive and can be
used to determine the levels of different
hydroxylated PAHs in urine.
Individual susceptibility. As evident
from the discussion above, the genotoxic
activity of a particular PAH requires meta-
bolic activation to the ultimate active form
and subsequent binding of these intermedi-
ates to critical positions in DNA. It can also
be assumed that the extent of DNA binding
in conjunction with the qualitative and
quantitative distribution of adducts and
their structures are intimately associated
with mutagenic and carcinogenic potency.
Given that the results obtained in experi-
mental systems of animal origin are applica-
ble to the human situation, interindividual
differences in the enzyme/enzyme systems
participating in the metabolism of PAHs are
expected to play an important role in the
tumor susceptibility of an individual.
Polymorphisms in the enzymes participating
in the activation of PAHs to their ultimate
mutagens and the subsequent detoxiﬁcation
and elimination of these intermediates have
been identified in humans. The balance
between the rate of formation of reactive
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and the rate of their elimination on the
other are expected to be directly correlated
with the extent of DNA binding.
Accordingly, variations in the cytochrome
P450s, EHs, peroxidases, NAD(P)H:
quinone oxidoreductases, and GSTs seem to
be the most important determinants of the
individual susceptibility to DNA adduct
formation from PAHs.
Cytochrome P450. As mentioned
earlier, CYP1A1 is the cytochrome P450
isoenzyme most active in the metabolic acti-
vation of PAHs. Cigarette smoke induces
both CYP1A1 protein levels and the metab-
olism of BP to fluorescent phenols. This
activity is usually referred to as aryl hydro-
carbon hydroxylase activity (AHH) in the
lung (Anttila et al. 1991). Furthermore, a
positive correlation has been reported
between the incidence of lung cancer and
the inducibility of AHH in human lympho-
cytes (Gahmberg 1979; Kellerman et al.
1973; Kiyohara et al. 1998). Certain alleles
of the human CYP1A1 gene have been
implicated both in lung cancer and in
prostate cancer in Japan (Hayashi et al.
1992; Murata et al. 1998; Rojas et al. 2000),
but these observations have not been repro-
duced in studies on Caucasian populations
where the indicated alleles appear at much
lower frequencies. Two closely linked muta-
tions in particular have been studied exten-
sively in relation to cancer risks; one results
in a new restriction site (MspI) in the 3´
untranslated region of the gene, and the
other is a mutation in the 7th exon that
results in an amino acid exchange (Ile to
Val). A growing number of studies link the
mutations in the CYP1A1 gene to increased
susceptibility to DNA damage. The allele
carrying the Ile to Val mutation was more
commonly found in lung parenchyma DNA
from lung cancer patients and in white
blood cells from PAH-exposed individuals
with high levels of DNA adducts derived
from anti-BPDE (Rojas et al. 1998, 2000).
This allele was also associated with increased
occurrence of p53 mutations in tumor tissue
(Kawajiri et al. 1996; Lazarus et al. 1998;
Przygodzki et al. 1998). In some studies, but
not all, it has been associated with higher
AHH inducibility (Daly et al. 1998;
Kiyohara et al. 1998; Wedlund et al. 1994).
Another cytochrome P450 enzyme
recently identified in humans, CYP1B1, is
also induced by PAHs. There are at least four
common mutations resulting in amino acid
exchanges in the human CYP1B1 gene,
which may explain some of the variation in
human AHH activity (Stoilov et al. 1998).
Finally, a recent study shows considerable
variation in the human pulmonary CYP3A4
and CYP3A5 expression (Anttila et al. 1997). 
Epoxide hydrolase. Microsomal EH
catalyzes the hydrolysis and thus, the detoxi-
fication of epoxide intermediates of PAHs.
The human EH gene was recently isolated
and two relatively common amino acid vari-
ants were characterized (Hassett et al. 1994).
Thus, human EH polymorphism exists and
may cause interindividual differences in EH
catalytic function.
Myeloperoxidase. A-463 G to A poly-
morphism in the promoter region of the
human myeloperoxidase (MPO) gene,
which leads to the loss of an SP1 transcrip-
tion binding site in an Alu hormone-respon-
sive element, reduces MPO mRNA
expression. The in vivo formation of
BPDE–DNA adducts in human skin treated
with coal tar was reduced in the MPO-
463AA/AG genotype compared with the
GG genotype (Rojas et al. 2001).
NAD(P)H:quinone oxidoreductase. In
humans, a C to T base change at position
609 of NAD(P)H:quinone oxidoreductase 1
(NQO1) RNA, which changes proline in
the wild-type protein to serine in the mutant
protein, has been demonstrated. This muta-
tion results in the loss of NQO1 activity.
The NQO1 protein catalyzes the metabolic
detoxiﬁcation of quinones and their deriva-
tives. NQO1 has been reported to specifi-
cally prevent the formation of B[a]P
quinone–DNA adducts generated by
CYP1A1 and P450 reductase (Joseph and
Jaiswal 1994) and NQO1–/– mice had an
increased susceptibility to B[a]P-induced
skin carcinogenesis (Long et al. 2000).
Glutathione transferases. Glutathione
transferase-catalyzed conjugation of DE and
the subsequent enzyme-mediated transport
of the water-soluble glutathione (GSH) that
conjugates out from the cell is probably the
most important system of protection. Several
classes of cytosolic human GST (Alpha, Mu,
Pi, Theta, and Zeta) have been deﬁned, and
each class contains a variable number of
closely related enzyme variants, or iso-
enzymes (Board et al. 1997; Mannervik and
Widersten 1995). The catalytic efﬁciency of
different GSTs (isoenzymes of Alpha, Mu,
and Pi have been tested so far) with respect
to a number of DE diastereomers and their
corresponding enantiomers varies markedly.
In addition, certain isoenzymes, for example,
those belonging to class Pi, exhibit an exclu-
sive preference for the DE enantiomers with
R-absolute configuration at the benzylic
arene carbon (of the DE isomers identified
as ultimate carcinogens), whereas others
(e.g., class Alpha and Mu isoenzymes) are
less selective (Sundberg et al. 1997). 
Several epidemiologic studies have been
performed to establish a correlation between
the GST genotype and the incidence of
lung cancer due to cigarette smoking and
consequent high exposure to various PAHs.
A great deal of interest has been focused on
class Mu GST, in particular GSTM1-1, as a
high and (depending on ethnic group) vari-
able proportion of individuals lack this
isoenzyme. Accordingly, because it is sus-
pected that the PAHs in cigarette smoke are
involved in lung carcinogenesis, and because
GSTM1-1 actively detoxiﬁes DE by conju-
gation with GSH, individuals with low
GST activity may be at a higher risk than
individuals expressing high conjugating abil-
ity. The association between GSTM1 poly-
morphism and lung cancer is still
controversial. It has been investigated in
numerous epidemiologic studies. Two
recent meta-analyses of case–control studies,
1 of 21 studies (d’Errico et al. 1999) and
1 of 23 studies (Houlston 1999), reported a
positive association between GSTM1 defi-
ciency and lung cancer. The suggested asso-
ciations are weak and not observed in all
studies but are reportedly stronger among
Asians and for squamous cell and small cell
carcinomas (Vineis et al. 1999). The most
obvious explanation for the weak association
between GSTM1-1 deficiency and lung
cancer risk is that GSTM1-1 is not highly
expressed in the respiratory tract. 
In biomarker studies, the levels of DNA
damage in peripheral lymphocytes from
smokers were higher in some instances in
donors with the GSTM1-null genotype
compared with GSTM1-positive donors
(Scarpato et al. 1997; van Poppel et al.
1992). These ﬁndings were substantiated in
a recent study (Rojas et al. 1998, 2000) in
which convincing evidence was presented
for the involvement of GSTM1-1 in protec-
tion against the formation of DNA adducts
derived from anti-BPDE. In a total of 40
individual DNA samples obtained from
lung tissue from smokers with lung cancer
and white blood cells from PAH-exposed
coke-oven workers, no adducts ascribed to
anti-BPDE were detected in any of the 23
individuals carrying active GSTM1 genes,
whereas all of the subjects with the GSTM1-
null genotype had measurable levels of
DNA adducts. 
Studies on a possible protective role of
class Pi and Theta GST in human carcino-
genesis have also been conducted. The major
GST in human lung is GSTPi; this enzyme
detoxifies a number of PAH DEs by GSH
conjugation. Two polymorphic sites are
known, at codon 105 and codon 114 in the
human GSTP1 gene, that may alter the
kinetic properties of the enzyme. In fact,
replacing isoleucine at position 105 by ala-
nine in GSTP1-1 signiﬁcantly increases the
conjugating activity toward various DE sub-
strates (Sundberg et al. 1998a, b).
Interestingly, DNA adducts believed to
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cells in newborns are considerably lower in
those expressing GSTP1 ile/ile than those
with GSTP1 val/val, thus suggesting a pro-
tective role of the latter isoenzyme (Whyatt
et al. 2000). With respect to lung cancer in
humans and exposure to PAH-containing
material, the results from studies on GSTPi
and Theta polymorphism are too limited
and variable to allow any definite conclu-
sion. However, the importance of GSTPi in
tumor susceptibility was recently demon-
strated in mice treated with the PAH 7,12-
dimethylbenz[a]anthracene and the tumor
promoter TPA. The tumor incidence in ani-
mals in which the GSTP1 gene cluster had
been deleted was more than three times
higher than in normal mice (Hendersson
et al. 1998). Accordingly, in addition to
GSTPi polymorphism in individuals, varia-
tion in the phenotypic expression of the
enzymes may also be a factor to consider in
the context of tumor susceptibility.
Absorption, Disposition, and
Metabolism of PAHs in the
Respiratory Tract
As discussed previously, PAH-containing
matter may enter the human body via the
respiratory tract, the digestive tract, and the
skin. Because this document deals primarily
with airborne PAHs and human exposure
via the respiratory tract, we discuss this route
in more detail here.
Transport and PAH metabolism in the
airway epithelium. Recent experiments on
dogs have shown that after a low-level expo-
sure of a highly lipophilic compound (i.e.,
B[a]P or pyrene) via the respiratory tract, a
substantial part of the substance is selectively
retained in the tracheobronchial epithelium.
These observations raise important questions
related to the effective dose of PAHs in the
airway epithelium of humans: a) What is the
significance of the fact that most carcino-
genic PAHs are to a high extent associated
with airborne particles? b) How fast are
PAHs transported from different regions of
the respiratory tract into the circulatory sys-
tem? and c) What is the relative contribution
of the seemingly modest metabolic capacity
of lung tissues compared with the liver in the
overall formation of ultimate DNA-binding
intermediates to which target cells are
exposed?
Early studies on the inﬂuence of particle
association of PAHs on carcinogenicity in
animals indicated that particles increase the
carcinogenicity of PAHs by prolonging the
retention of the compounds in the lung,
thereby increasing the effective dose (Henry
and Port 1975). However, the experiments
were conducted by instilling very large
amounts of particles and PAHs into rodents,
and most likely the observed effect of the
particles was the artefactual consequence of
the extreme dosing scenario. This observa-
tion is important, as the early results sug-
gested that a certain particle-retained
fraction of PAHs would be more carcino-
genic in the lung than fractions that are
rapidly eluted from the particles. In addi-
tion, the findings masked the behavior of
PAHs at realistic exposure levels. PAHs that
are desorbed from their carrier particles
absorb within minutes into the blood from
the thin alveolar epithelium (Gerde et al.
1993) but more slowly from the thicker
epithelia of the conducting airways.
The prime determinant for the rate of
absorption of organic compounds through
the tracheobronchial epithelium is their
lipophilicity; the more lipophilic the com-
pound, the lower the rate of diffusion
through the tracheobronchial epithelium
into the circulatory system (Figure 13). For
highly lipophilic carcinogens such as B[a]P,
the delayed absorption in the airway mucosa
is entirely the result of slow passage through
the tracheobronchial epithelium, giving a
very high dose to these target cells (Gerde et
al. 1998). When the compound reaches the
circulation following diffusion through the
epithelium basement membrane and the
endothelium, the immense transport capac-
ity of the blood will rapidly dilute it to the
low level at which all distal tissues are
exposed. The effect of the highly localized
dose in the airway epithelium can easily be
overlooked, or confused with artefactual
effects of particles with which the compound
is associated.
By decreasing the lipophilicity of a toxic
compound and thereby enhancing the rate
of clearance to capillary blood, metabolism
is an integral part of the removal of harmful
substances from the conducting airways.
Because of the long retention time of
lipophilic compounds in the epithelium at
the site of entry, the metabolic conversion
can be substantial even at low enzyme activ-
ities (Bond and Harkema 1988). The ulti-
mate carcinogenic metabolites generated in
this process, such as BPDE in the case of
B[a]P, are still quite lipophilic (Ooi et al.
1994), and they can be expected to be
retained in the airway epithelium. Increased
local concentrations in airway target cells
can thus be anticipated. Therefore, at low
inhalation exposure levels, the contribution
of reactive PAH intermediates generated
locally in the airway epithelium probably
dominates over the contribution of corre-
sponding metabolites formed in the liver
and subsequently transported to the lungs
via the systemic circulation. At higher expo-
sure levels, however, the liver seems to be
the dominant contributor of active metabo-
lites in the lungs (Wall and Gao 1991;
Wiersma and Roth 1983).
Site of formation of DNA-binding
intermediates. Exposure of experimental
animals to PAHs results in adduct forma-
tion in most tissues. However, the relation-
ship between adduct levels in different
tissues and cancer risk is not yet clear. At
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Figure 13. A schematic representation of the two major mechanisms of the absorption of organic carcinogens in the
tracheobronchial mucosa. Abbreviation: t, time. Two concentration proﬁles are indicated in each cross-section, sepa-
rated by typical time intervals. Water-soluble to moderately lipophilic carcinogens, i.e., the tobacco-specific
nitrosamines, are blood-ﬂow limited during absorption in the mucosa. Such substances diffuse rapidly into the capil-
lary bed and are taken up by the blood during time periods on the order of minutes. The exposure at the site of
absorption will be brief and not very different from that of distal tissues exposed via the systemic circulation (A).
Highly lipophilic carcinogens such as PAHs are diffusion limited in their absorption in airway mucosa. PAHs diffuse
slowly along steep concentration gradients through the airway epithelium, and they are likely to enter the systemic
circulation via the most superﬁcial capillaries of the subepithelium (B). Even after a brief exposure, the site-of-entry
epithelium will be selectively exposed for hours at considerably higher concentrations than the rest of the organism.
Figure modiﬁed from Gerde et al. 1993.higher exposure levels the quantity of
adducts per unit weight of total tissue seems
to be less dependent on the administration
route (Boroujerdi et al. 1981; Bresnick and
Eastman 1982; Kleihues et al. 1980). This
was recently illustrated in repair-deficient
mice after administration of B[a]P by stom-
ach gavage. The level of DNA adducts after
7 weeks of exposure was approximately the
same in different organs (Helleberg et al.
2001). These findings imply that the liver,
as the major site for biotransformation of
xenobiotics, participates in the metabolism
of PAHs independently of the route of
entry. It is believed that primarily formed
metabolites, or the ultimate reactive inter-
mediates, are formed in the liver and subse-
quently released into the circulation and
transported to extrahepatic tissues. It should
be emphasized, however, that these tissues
also possess the ability to activate PAHs to
reactive intermediates. 
In the lung, the highest expression of
CYP1A1 has been reported in the terminal
bronchiolar epithelium (Mace et al. 1998;
Saarikoski et al. 1998). Of interest also is the
CYP1A1-dependent metabolic capacity of
the endothelial cells (Granberg et al. 2000
and references therein). The vascular
endothelium makes up approximately 1% of
the body weight of humans, which implies
that the metabolically active endothelial cells
could serve as an important site for forma-
tion of reactive metabolites. Moreover, the
above experiments were made at high expo-
sure levels, with the potential for saturation
of activation in the site-of-entry epithelium.
At realistic exposure levels, the relative
importance of activation in the airway site-
of-entry epithelium is likely to be greater.
Dosimetry. In estimating the risk of lung
cancer from inhaled PAHs, three aspects of
their distinctive site-of-entry dosimetry are of
particular importance: a) the relationship
between biomarkers of exposure in the sys-
temic circulation and the dose of PAHs and
relevant metabolites in airway target cells,
b) the saturation of PAH metabolism and lim-
ited solubility of the parent compound and
metabolites in the airway mucosa, and c) the
dose response of the particular PAH inhaled.
During normal exposure to PAH-
containing aerosols, a major fraction (proba-
bly >80%) of the inhaled PAHs is expected
to be deposited on the thin alveolar epithe-
lium. and is rapidly absorbed into the blood.
The major part of this fraction is not metab-
olized during absorption in the lungs (Gerde
et al. 2001) but in the liver. A minor fraction
(<20%) is absorbed and metabolized in the
tracheobronchial epithelium (Figure 14).
This leads to great uncertainty when investi-
gators try to estimate the target dose of a
compound in the airway epithelium by
quantifying the metabolites in the systemic
circulation or DNA adducts in blood cells
(Gerde et al. 1997, 1998), particularly if the
activation of PAHs proceeds differently in
the liver relative to the lungs. The second
important aspect of the PAH dosimetry is a
likely nonlinear dose–response relationship.
The lipophilic PAHs that penetrate the
mucous lining layer dissolve readily in the
bronchial epithelial membranes but are
transported slowly into the capillary blood.
This process is dependent on the lipophilic-
ity of the PAH; for example, B[a]P compris-
ing five benzenoid rings partitions more
readily into the membranes than into cellu-
lar water compared with pyrene comprising
four rings. As a consequence, B[a]P is
released more slowly into the circulatory sys-
tem (Gerde et al. 1997, 1998). Therefore,
the bronchial epithelium attains high PAH
concentrations even at low environmental
exposure levels. At higher levels, the capacity
of the airway epithelium to dissolve and
metabolize PAHs is likely to be saturated.
Although unaccounted for in an experi-
mental exposure scenario, these limiting
capacities may introduce drastic nonlineari-
ties between exposure and airway target
dose. However, because of the large meta-
bolic capacity of the liver, the major fraction
of PAHs absorbed into the blood from the
thin alveolar epithelium is not likely to satu-
rate hepatic metabolism even at high expo-
sure levels. Accordingly, any saturation of
metabolism in the airway epithelium, if mea-
sured in the systemic circulation, is likely to
be masked by the larger contribution of
metabolites formed and released from the
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Figure 14. A schematic representation of the two major routes of entry of PAHs via inhalation. A major fraction is
deposited on the thin air–blood barrier of the alveolar type I cells, and it is rapidly absorbed and diluted in the sys-
temic circulation. Despite the larger fraction absorbed here (absorbed dose), type I cells will experience a compara-
tively low tissue dose of inhaled PAHs. A minor fraction is deposited on the thicker bronchial/bronchiolar epithelium
and it is rapidly absorbed into epithelial cells, but it is transported slowly into the circulating blood. Very high tissue
doses of inhaled PAHs will result in these cells, and carcinogenicity at the site of entry is likely to dominate com-
pletely over contributions to carcinogenicity delivered with the systemic circulation.
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epitheliumliver. A likely consequence for highly
lipophilic PAHs is that risk assessments
based on animal exposures conducted at
exposure levels exceeding such a saturation
may underestimate cancer risk in humans
after decades of environmental exposure
(Gerde et al. 1997, 1998). However, a better
understanding of the way in which inhaled
PAHs are distributed in target and nontarget
tissues will improve the feasibility of extrapo-
lating dose–response relationships to the low
levels at which humans are exposed and help
to improve the interpretation of the results
from various biomarkers of exposure.
Conclusions and Recommendations
for Indicators for Environmental
PAHs
Experiments on animals and in mammalian
cells have revealed that several PAHs are
mutagenic and carcinogenic, and that these
activities are associated with certain proper-
ties of the compounds. For both alternant
(e.g., B[a]P and dibenzo[a,l]pyrene) and
nonalternant PAHs (e.g., benzo[b]fluor-
anthene and cyclopenta[c,d]pyrene), the
mutagenic and ensuing carcinogenic activi-
ties depend on metabolic activation to reac-
tive intermediates (in particular DEs) and
their covalent binding to critical targets in
DNA. In addition to the mutagenic
potency, many PAHs exhibit a cancer-
promoting ability, for instance, via interac-
tion of the parent PAH with a cellular
receptor. The promoter activity may lead to
very high tumor incidences in animals
exposed to high doses. If based on animal
experiments, carcinogenic potency may
therefore overestimate the risk at the low
exposure levels in the general environment,
where mutation is expected to play a pre-
dominant role. The mutagenic and carcino-
genic potency of a PAH is associated with
the structural features and the complexity
of the molecule; a more complex com-
pound is usually more potent. 
A number of epidemiologic studies have
demonstrated a close association between
exposure to PAH-containing mixtures and
an increased risk of tumor formation in
humans. This correlation is particularly evi-
dent for cigarette smokers and primary can-
cers in the respiratory tract. Accordingly,
reduction and ultimately elimination of
PAHs from the environment is expected to
reduce the incidence of PAH-induced
tumors. Factors likely to influence the sus-
ceptibility of an individual toward PAH
exposure include polymorphisms in genes
encoding enzymes participating in the
metabolism of the PAHs (e.g., cytochromes
P450 and GSTs).
An important route of exposure to
PAHs in ambient air in humans is via
inhalation. Because of the lipophilic
properties of PAHs, fractions of the com-
pounds are likely to be retained in the lung
tissue and attain high local concentrations
even at the low levels of exposure to which
humans are subjected. The retention is
related to the lipophilicity of the com-
pounds; the more lipid soluble the com-
pounds are, the more efficient is the
retention. At higher exposure levels the
capacity of the airway epithelium to retain
the compounds becomes saturated, and
nonlinearities between exposure and airway
target dose can be expected.
For human monitoring purposes, a
number of analytic methods have been
applied for determining PAH exposure.
DNA adducts and blood–protein adducts of
aromatic compounds have been analyzed,
particularly in association with cigarette
smoking and occupational exposures. There
are still problems with regard to the sensitiv-
ity and specificity as well as the stability of
different adducts; this renders such methods
less suitable at present for use in routine bio-
logical monitoring. Determination of
hydroxylated PAH metabolites in urine can
be used to detect specific metabolites. The
determination of 1-hydroxyphenanthrene in
urine is sensitive enough to quantify expo-
sure at environmental PAH levels.
Therefore, risk assessment based on animals
exposed to high levels of PAHs may under-
estimate cancer risks in humans after decades
of environmental exposures.
To form a basis for action against PAHs
in the environment, frequent monitoring of
selected PAH species under various condi-
tions is essential. The choice of compounds
should be based on both practical and bio-
chemical/biological considerations. Because
of their abundance in the environment, com-
pounds such as phenanthrene and pyrene are
suitable indicators for PAH contamination in
general and overall human exposure to
PAHs. However, substances such as ﬂuoran-
thene, B[a]P, and dibenzo[a,l]pyrene are
suitable carcinogenic indicators.
Quantitative Cancer Risk
Estimates
Cancer risk assessment of individual PAHs
and PAH mixtures are based mainly on
tests on laboratory animals and occupa-
tional epidemiologic studies. For several
reasons, risk estimation of PAH exposures
is a complex issue. 
PAHs in the environment comprise
several hundred compounds, most of which
occur together with substituted PAHs and
with a large number of other carcinogenic
pollutants. The composition profile of the
PAHs, as well as of other pollutants
simultaneously present, varies between
environmental compartments, for example,
different occupational settings. This ren-
ders risk estimates for the whole mixture
based on epidemiologic studies, with data
on exposure restricted to one or a few
components, very uncertain.
Individual PAHs may provoke a cancer
risk by more than one mechanism (initiation
of tumor formation and effects on the tumor
development at later stages), often in interac-
tion with other inherited or acquired factors
(cf. “Mechanistic Aspects of Biological
Activity”). The mechanisms operate with
different dose–response relationships, and it
is difficult to clarify which mechanism has
been mainly causative in the effect observed
in animal cancer tests where very high doses
are often applied. This strongly contributes
to the difﬁculties in obtaining reliable cancer
risk estimates with relevance for the human
situation, usually characterized by low expo-
sure levels. 
Nevertheless, at the present stage of
knowledge, risk estimation for PAHs at low
exposure levels should be based on the
assumption of linear dose–response relation-
ships despite the nonlinear responses often
seen for high doses in animal tests. 
Because the scientiﬁc basis for quantita-
tive risk assessment of inhaled PAHs is weak,
the basis for recommended guideline values
in ambient air is accordingly also weak. It is
thus important for the Swedish regulatory
agency, the Swedish Environmental
Protection Agency, to gain experience in
how risk assessment of PAHs has been han-
dled in other countries. A survey is presented
in this section. 
Epidemiologic Data
As mentioned earlier (Table 1), exposure to
soot, coal tar, and other PAH-containing
mixtures is carcinogenic to humans.
Concerning inhalation exposure, tobacco
smoking and certain occupational exposures
within the aluminum production, coal gasi-
fication, and coke production industries
have been classified by IARC as carcino-
genic to humans. Diesel exhaust is classiﬁed
as probably carcinogenic to humans. More
recent epidemiologic studies have been
reviewed inter alia by Mastrangelo et al.
(1996) and Boffetta et al. (1997). These
studies confirm that heavy occupational
exposure to mixtures of PAHs entails a sub-
stantial risk of lung, skin, or bladder cancer.
Exposure–response relationships have been
demonstrated in several studies, although
quantitative risk estimates relative to PAH
levels are conﬁned mainly to lung cancer in
coke-oven workers. 
The increased risk for lung cancer
among coke-oven workers is used for the
quantitative risk assessment of PAHs with
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the Air Quality Guidelines for Europe
(WHO 1987, 2000). According to WHO
(1987), a strongly increased risk of death
from cancer of the respiratory system had
been demonstrated among workers at coke
ovens in Allegheny County, Pennsylvania,
USA, for 1953–1970, especially in top-oven
workers (relative risk [RR] = 6.6–15.7 for
some 300 topside, full-time workers, divided
into different categories according to the
years of exposure). WHO (1987) further
refers to a risk assessment by the U.S.
Environmental Protection Agency (U.S.
EPA) in 1984 that applied a linearized mul-
tistage mathematic model to the individual
exposure estimates, which generated an
upper-bound risk estimate expressed in
terms of benzene-extractable material. The
U.S. EPA estimate was converted in terms
of B[a]P levels by assuming a 0.71% con-
tent of B[a]P in the benzene extract, thus
estimating the lung cancer risk from a life-
time exposure to PAHs in ambient air at 8.7
× 10–5 per ng/m3 B[a]P (WHO 1987,
2000). The difficulties in dealing with
guidelines for PAH mixtures are discussed,
as are the advantages and disadvantages of
using a single indicator carcinogen to repre-
sent the carcinogenic potential of a fraction
of PAHs in air. It is stated that no specific
guideline can be recommended for individ-
ual PAH compounds in air. An evaluation
of B[a]P alone, for example, is likely to
underestimate the carcinogenic potential of
airborne PAH mixtures, because other
co-occurring substances are carcinogenic as
well. A complicating factor is that PAHs in
air are adsorbed onto particles, which may
also play a role in their carcinogenicity.
B[a]P was chosen as an indicator of carcino-
genic PAHs in ambient air, although the
limitations and uncertainties in such an
approach were recognized. WHO does not
set guideline values for genotoxic carcino-
gens such as PAHs because no safe level can
be recommended, but it specifies a risk
estimate as a basis for policy makers. 
Using measurement data on PAHs from
German coke ovens applied to the same epi-
demiologic data on coke-oven workers, Pott
(1985) calculated a similar risk (5 × 10–5 per
ng/m3 of B[a]P).
An update of this cohort and the
mortality among other coke-oven workers
in Pennsylvania, USA, providing 30 years
of follow-up, has been presented
(Costantino et al. 1995). The results are
consistent with those from earlier assess-
ments, indicating an excess mortality from
cancer of the respiratory system.
An earlier quantitative risk estimate
based on lung cancer in workers in British
gas works (Pike 1983) gave a higher estimate
(43 × 10–5 per ng B[a]P/m3) than the WHO
risk estimate. 
The exposure to PAHs in an aluminum
production plant (Armstrong et al. 1994)
gave a quantitative risk estimate of 1 × 10-5
per ng B[a]P/m3 as workplace exposure for
40 years. If converted to lifetime continuous
exposure, the corresponding lifetime unit
risk for respiratory cancer would be approxi-
mately 9 × 10–5 per ng/m3 (70/40 years ×
365/220 days × 24/8 hr). This risk ﬁgure is
identical to the WHO risk estimate based on
coke-oven workers.
For most other occupational studies,
quantitative risk estimates cannot be derived
because of lack of exposure estimates. For
example, an increased risk for lung cancer in
Swedish chimney sweeps has been demon-
strated (Evanoff et al. 1993).
Several epidemiologic studies have
demonstrated an increased risk of lung cancer
in persons occupationally exposed to diesel
exhausts, for example, American railroad
workers (Garshick et al. 1987, 1988) and
Swedish dock workers (Emmelin et al. 1993;
Gustafsson et al. 1986) and bus garage work-
ers (Gustavsson et al. 1990). These studies
have not yet provided quantitative risk esti-
mates relative to PAHs. However, Pott and
Heinrich (1990) made a rough comparison
of the amount of B[a]P inhaled from diesel
exhaust and coke-oven emissions that would
induce a certain incidence of lung tumors.
These authors concluded that a much smaller
amount of B[a]P was needed in diesel
exhaust than in coke-oven emissions.
The lung cancer risk associated with
smoking is well characterized, but when
the risk is compared with the risk in coke-
oven workers on a B[a]P basis, the amount
of B[a]P inhaled has a much lower signifi-
cance for the carcinogenicity of cigarette
smoke than for coke-oven emissions (Pott
and Heinrich 1990). Thus, both diesel
exhaust and cigarette smoke obviously con-
tain other potent carcinogenic substances
besides PAHs. For example, it is known
that cigarette smoke contains gas-phase
carcinogens and tumor promoters, and
diesel exhaust contains nitro-PAH (IARC
1987b, 1989b).
Because the content of unsubstituted
PAHs is probably responsible for only part
of the carcinogenicity of cigarette smoke
and diesel exhaust, these exposures are less
well suited for a quantitative risk assessment
of PAHs.
The incidence of lung cancer is generally
higher in urban areas than in rural areas.
This difference can be attributed partly to air
pollutants. According to a review of 9 cohort
studies and 13 case–control studies world-
wide (Pershagen and Simonato 1993),
smoking-adjusted relative risks of lung
cancer in urban areas were generally on the
order of 1.0–1.5. Exposure data on the levels
of PAHs are generally lacking in these stud-
ies, and they cannot be used for a quantita-
tive risk estimation of PAH or B[a]P.
A high rate of lung cancer has been
described for women in Xuan Wei in China
as a result of cooking with smoky coal with-
out proper ventilation. According to the
RIVM (1989), the average B[a]P level was
14.7 µg/m3. Tuomisto and Jantunen (1987)
used these data for a quantitative estimate of
the risk of lung cancer, which extrapolated to
low levels would give a unit risk value of 6.7
× 10-5 per ng/m3 B[a]P (RIVM 1989). We
have not found any other quantitative risk
estimate in the literature based on these data.
Some of these risk estimates mentioned
were cited in a Dutch criteria document on
PAHs (RIVM 1989), and a risk of 10 × 10–5
per ng/m3 B[a]P (as an indicator of carcino-
genic PAHs) was considered the most appro-
priate value.
In a Canadian PAH document by
Muller (1997), the risk assessment was
based on the data from U.S. coke-oven
workers, but the estimate (2.3 × 10–5 per
ng/m3 B[a]P) was lower than the WHO
estimate because the maximum likelihood
estimate was used instead of the upper-
bound estimate. Muller (1997) also esti-
mated that the risk for B[a]P as such was
1.5 × 10–6 per ng/m3, assuming that 15%
of the carcinogenicity of coke-oven emis-
sions is due to B[a]P, which is indicated by
the potency ratio between extracts of partic-
ulate emissions from a coke-oven and B[a]P
in a mouse skin initiation study (Nesnow
et al. 1982).
Muller (1997) also discussed the two
main approaches to risk assessment of PAH
mixtures, namely, either to estimate the
potency of individual PAHs based on animal
data and sum up the risks, or to estimate the
potency of the PAH fraction as a whole,
based on epidemiologic data and using
B[a]P as indicator substance. According to
these authors, a comparison of the two mod-
els suggests that the individual PAH model
underestimates the risk based on epidemiol-
ogy by almost two orders of magnitude. This
result is consistent with the predictions, as
the individual PAH model takes into
account the risk attributable to only a hand-
ful of PAH compounds. An uncertainty
assessment indicated that the epidemiology
approach is associated with a much lower
uncertainty than the individual PAH model.
In Great Britain, an Expert Panel on Air
Quality Standards has prepared a report on
PAHs (Expert Panel 1999). Based on the
similarity of the PAH profiles in urban air
and in an aluminum smelter workplace
(seven measured PAH compounds; see
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cluded that occupational studies on workers
at aluminum smelters form a suitable basis
for recommending an environmental stan-
dard. The study chosen was the Canadian
study on aluminum workers by Armstrong
et al. (1994). In this study, a 50% increase in
the risk of lung cancer was demonstrated,
with a cumulative exposure to B[a]P as indi-
cator substance at levels of 10–100 µg/m3 ×
year (equivalent to an exposure to 0.25–2.5
µg/m3 B[a]P for 40 years). A safety factor
approach was then used to derive a recom-
mended ambient air quality standard.
Recalculating from a working-life exposure
to continuous lifetime exposure (a factor of
10), using a safety factor of 100, leads to a
recommended value of 0.25 ng/m3 B[a]P as
an annual average.
The WHO risk estimate was used by the
Swedish Governmental Commission on
Environmental Health (Commission on
Environmental Health 1996) when propos-
ing an action plan for Sweden to reduce
environmental health risks. A target was set
up for PAHs with B[a]P as the indicator
substance at 0.1 ng/m3 as the long-term
average. This level corresponds to a theoretic
lifetime cancer risk of 1 × 10–5, according to
the WHO risk assessment.
Data from Animal Experiments
Experiments with benzo[a]pyrene. The best-
investigated single PAH compound is B[a]P.
Besides dermal exposure, B[a]P is carcino-
genic by intraperitoneal injection, intratra-
cheal instillation, inhalation, and when given
in the diet. For our discussion, the inhala-
tion route is the most relevant one.
However, the inhalation study by Thyssen
et al. (1981) is the only one found in
Western scientific literature. Groups of 24
male hamsters were each exposed to B[a]P
condensed onto sodium chloride particles at
concentrations of 2.2, 9.5, and 46.5 mg/m3
for 4.5 hr/day, 7 days/week for the first 10
weeks, then for 3 hr per day. Exposure was
by nose breathing only. There were no
tumors in the low-exposure group or in the
control group. In the other groups, expo-
sure-related tumors were found in the nasal
cavity, larynx, trachea, pharynx, esophagus,
and forestomach. However, there were no
tumors in the lung. The average survival
time was lower in the highest exposure
group: 59 weeks compared with 96 weeks
for the control group. This study has been
used for quantitative risk assessment using
the so-called linearized multistage model.
The upper bound of the 95% confidence
limit of the dose–response curve was used to
calculate the risk corresponding to a speciﬁc
inhalation dose. However, because of the
high mortality in the highest dose group,
these data had to be omitted; as there were
no tumors in the lowest dose group, the cal-
culation will actually be based on only one
dose group. Moreover, there were relatively
few animals per dose group, and the study
was not reported according to modern stan-
dards. Thus, the resulting estimates will be
quite uncertain. According to Collins et al.
(1991), a linearized multistage model using
three different assumptions concerning the
inhalation rate in hamsters will give so-called
unit risk estimates for humans at 0.37 ×
10–6, 1.1 × 10–6, and 1.7 × 10–6 per ng/m3,
respectively. These unit risk ﬁgures indicate
the theoretic increased lifetime risk for respi-
ratory tract tumors resulting from continu-
ous inhalation of 1 ng/m3 for a lifetime, and
they were obtained by converting the inhala-
tion regimen in the animal experiments into
continuous exposures and using a species
conversion factor from hamster to humans
based on inhaled dose per body surface area.
The higher estimate, 1.7 × 10–6 per ng/m3,
was used by the U.S. EPA in 1984, but
because of the inadequacies of the study by
Thyssen et al., the U.S. EPA currently has
no official quantitative inhalation risk esti-
mate for B[a]P (IRIS 2001). However, the
California EPA uses the middle estimate, 1.1
× 10–6 per ng/m3 (CARB 1994). In a Dutch
criteria document on PAHs (RIVM 1989),
the risk was estimated to be 0.28 × 10–6 per
ng/m3. (Note that this risk is smaller than
that calculated by Collins above because no
upper conﬁdence limit or species conversion
factor was applied.)
According to the Dutch criteria docu-
ment there was a Russian inhalation study
with mice (Knizhnikow et al. 1982, cited in
RIVM 1989), in which malignant lung
tumors were found, which indicates a much
higher risk than the study by Thyssen et al.
(1981). In this study, female white mice
were exposed to 0.2, 6.3, or 78 µg/m3 B[a]P
as a dry aerosol, 6 hr daily, 5 days per week
for 3 months. According to the RIVM
(1989), linear extrapolation from the highest
equivalent lifetime concentration would give
a risk of 4 × 10–4 per ng/m3. However, this
study has not been cited in any other criteria
document on PAHs that we have reviewed.
The Dutch document (RIVM 1989)
also refers to an inhalation study with rats
by Laskin et al. in 1970, in which malig-
nant lung tumors were observed after expo-
sure to B[a]P in combination with sulfur
dioxide. By means of linear extrapolation,
this study would give a risk for rats of 0.59
× 10–6 per ng/m3.
Two studies using intratracheal instilla-
tion have also been used for quantitative risk
assessments. Saffiotti et al. (1972) adminis-
tered a mixture of B[a]P (0.25, 0.5, 1.0, or
2.0 mg) and Fe2O3 (hematite) (2 mg) in a
saline suspension to hamsters once a week
for 30 weeks. A dose-related increase in res-
piratory tract tumors was observed for all
groups of animals. In another experiment,
Feron et al. (1973) gave groups of 30 male
Syrian golden hamsters intratracheal doses of
0.06, 0.12, 0.5, or 1.0 mg B[a]P weekly for
52 weeks. A variety of tumors was produced
in a dose-dependent fashion throughout the
respiratory tract. Using the linearized multi-
stage model, Collins et al. (1991) estimated
the unit risk for humans, based on these
studies, to be 4.4 × 10–6 and 4.8 × 10–6
per ng/m3, respectively. 
The cited studies with B[a]P are far from
optimal for quantitative cancer risk assess-
ments. However, they are the only ones
available concerning respiratory tract expo-
sure. In the Dutch criteria document
(RIVM 1989), it was concluded that the
uncertainties in the extrapolation from ani-
mal experiments with B[a]P are too high to
justify a risk assessment for man.
PAHs have been assessed by
Environment Canada/Health Canada under
the Canadian Environmental Protection Act
(Government of Canada 1994; Meek et al.
1994). Because of the possible confusion
with concomitant exposure to other sub-
stances that may have contributed to the
observed effects, available epidemiologic data
(see “Epidemiologic Data”) were considered
inadequate to assess the health risks of PAHs
in humans. Instead, the Canadian risk assess-
ment is based on the carcinogenicity of
B[a]P and four other PAH compounds clas-
sified as probably carcinogenic to humans,
namely, benzo[b]fluoranthene, benzo[j]-
fluoranthene, benzo[k]fluoranthene, and
indeno[1,2,3-cd]pyrene. The carcinogenic
potency of B[a]P was obtained by multistage
modeling of the study by Thyssen et al.
(1981). For these substances the estimated
concentrations, expressed as B[a]P equiva-
lents, were calculated for different localities.
The priority for “analysis of options to
reduce exposure of the general population”
was considered “moderate to high.”
Experiments with mixtures. An inhala-
tion study performed by Heinrich and co-
workers (1994), in which female Wistar rats
were exposed to a coal tar/pitch aerosol, has
also been used for the calculation of a unit
risk. In this case the animals were exposed to
a mixture of PAHs, but the cancer risk was
related to the B[a]P content. Thus, B[a]P
was used as an indicator of carcinogenic
PAHs in the mixture, and the approach is
equivalent in this respect to the way B[a]P is
used as an indicator of PAHs in epidemio-
logic studies. Groups of 72 rats were exposed
to a coal tar/pitch aerosol containing either
20 or 46 µg/m3 B[a]P for 17 hr/day,
5 days/week for 10 or 20 months, followed
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months, respectively. The cumulative doses
of inhaled B[a]P of the four exposure groups
were 71, 142, 158, and 321 mg B[a]P/m3 ×
hr, and the corresponding lung tumor rates
were 4.2, 33.3, 38.9, and 97.2%. There was
no lung tumor in the control group. Using
the linearized multistage model, the lifetime
unit risk for lung tumors was calculated to
be 2 × 10–5 per ng/m3. In similar experi-
ments in which rats were exposed to coal
tar/pitch vapor condensed on the surface of
ﬁne carbon black particles, the resulting lung
tumor rate was about twice as high. 
Heinrich and co-workers have also per-
formed a lifelong inhalation study with rats
exposed to diesel exhausts. In this study,
tumor rates similar to those in the study
with pitch pyrolysis vapors were induced,
although the PAH content (measured as
B[a]P) was 100–1000 times lower (Pott and
Heinrich 1990). This result shows that diesel
exhaust contains other potent carcinogenic
or tumor-promoting compounds besides
unsubstituted PAHs. Further, mutagenicity
studies have shown that the most mutagenic
components of diesel exhaust seem to be
substituted PAHs such as nitro-PAH. The
particulate fraction of diesel exhaust is
known to cause inﬂammatory reactions that
may indirectly lead to tumors if the concen-
tration of particles in the inhaled air is so
high that it leads to so-called overloading in
the lung. Such particle-induced lung cancer
has also been demonstrated in rats from the
inhalation of inert particles (for a review, see
Camner et al. 1997). The cited quantitative
risk estimates are summarized in Table 12.
Comparative Cancer Potency 
of Individual PAH Compounds
Relative to B[a]P
The available experimental studies on B[a]P
are not ideal for a quantitative risk assess-
ment for inhalation lung cancer and those
for practically all other individual PAHs are
either inadequate or nonexistent. However,
many other PAH compounds are classified
by the IARC as probable or possible human
carcinogens, and several authors have used
data from various cancer tests to rank the
compounds according to cancer potency rel-
ative to B[a]P. Although such comparative
rankings are not based on inhalation experi-
ments but on other cancer tests, the results
may still be used for grouping of individual
PAH compounds as more or less potent. A
more potent PAH would be preferable over
a less potent one when selecting indicator
substances for ambient air, based on biologi-
cal activity. Such cited rankings are pre-
sented in Table 13 and are restricted mainly
to those PAHs for which more than one
author has presented rankings.
Toxic equivalency factors (TEFs) can be
used as a practical tool for regulatory pur-
poses for large groups of compounds with a
common mechanism of action (e.g., dioxin-
like compounds and PAHs) when there are
limited data except for one reference com-
pound, 2,3,7,8-tetrachlorodibenzo-p-dioxin
and B[a]P, respectively. The TEF concept is
based on the following assumptions:
• There is a reasonably well-characterized
reference compound.
• These are qualitatively similar toxic effects
for all members of the class.
• TEFs for different toxic end points are
similar.
• The toxic effects of different compounds in
a mixture are additive.
In the following text we will use the
abbreviation TEF to denote the cancer
potency of speciﬁc PAH compounds relative
to the potency of B[a]P. The TEF values are
not true values but are based on the best
available data, which in many cases are
scanty. The calculated TEF value can also
vary within the dose range; this may be a
problem, as animal studies are performed
with high doses and humans are exposed at
low concentrations. The TEFs should be
used with great caution, as studies on mix-
tures of individual PAHs have shown that
they may interact metabolically in a number
of ways (RIVM 1989). 
In the following text, TEF values for
individual PAHs are discussed mainly with
the aim of selecting biologically relevant
PAH compounds as indicators of carcino-
genic PAHs in ambient air. For this purpose,
the TEFs are especially interesting when
combined with actual concentrations of the
PAH compounds (see “Fluoranthene as an
indicator”). The purpose has not been to try
to estimate the cancer risk by calculation of
added individual risks.
Different toxic equivalency factor
schemes. Nisbet and LaGoy (1992) reviewed
earlier relative potency estimates in 1992 and
provided revised ones (Table 13). The end
points of the studies included carcinomas in
the lungs of rats exposed via intrapulmonary
administration; complete carcinogenesis in
mouse skin; papillomas and/or carcinomas
on mouse skin in initiation-promotion stud-
ies, sarcomas at the site of injection follow-
ing subcutaneous administration to mice;
and PAH–DNA adducts in in vitro studies.
Relative potency factors (estimates of TEFs)
were calculated using the data from each
study by applying the same mathematic
model of the dose–response relationship to
the data for each compound and comparing
the results to those obtained for B[a]P.
According to the authors, the approach
adopted by the U.S. EPA in 1984 was to
separate the PAHs into carcinogenic and
noncarcinogenic PAHs and then to regard
all the carcinogenic PAH compounds as
potent as B[a]P (TEF = 1). All noncarcino-
genic PAHs were given a TEF of 0 by the
U.S. EPA. The TEF values by Krewski et al.
(1989) (Table 13) were based on diverse
bioassay and related data, but those original
data are not shown in the article. Some other
earlier TEFs were considered to be unreason-
ably precise by Nisbet and LaGoy (1992).
The TEF values given by Nisbet and LaGoy
(Table 13) were rounded to the order of
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Table 12. Summary of unit risk estimates for B[a]P and for PAHs with B[a]P as the indicator substance
(life-time risk per ng/m3 of B[a]P). 
Basis for calculation Unit risk Reference
Animal experiments
Inhalation of B[a]P in hamsters (Thyssen et al. 1981) 0.28 × 10–6 a RIVM (1989)
Inhalation of B[a]P in hamsters (Thyssen et al. 1981) 0.37–1.7 × 10–6 b CARB (1994); Collins et al. (1991); 
Muller (1997)
Inhalation of B[a]P + SO2 in rats (Laskin et al. 1970  0.59 × 10–6 a RIVM (1989)
cit. RIVM 1989)
Inhalation of B[a]P in mice (Knizhikow et al. 1982  400 × 10–6 a RIVM (1989)
cit. RIVM 1989)
Intratracheal instillation of B[a]P in hamsters
Safﬁotti et al. (1972) 4.4 × 10–6 b CARB (1994); Collins et al. (1991) 
Feron et al. (1973) 4.8 × 10–6 b CARB (1994); Collins et al. (1991) 
Inhalation of coal tar/pitch aerosol with B[a]P as  20 × 10–6 b Heinrich et al. (1994)
the indicator substance 
Epidemiology (PAH with B[a]P as indicator)
U.S. coke-oven workers 87 × 10–6 WHO (1987, 2000)
U.S. coke-oven workers 23 × 10–6 Muller (1997)
U.S. coke-oven workers 50 × 10–6 Pott (1985)
U.K. gas workers 430 × 10–6 Pike (1983)
Smoky coal indoors in China 67 × 10–6 RIVM (1989)
Most appropriate estimate 100 × 10–6 RIVM (1989)
Aluminum smelters 90 × 10–6 Armstrong et al. (1994); converted 
from workplace exposure to 
continuous lifetime exposure
aLinear extrapolation. bLinearized multistage model.magnitude that according to the authors
appropriately reflects the actual state of
knowledge on the relative potencies. 
The TEF value for dibenz[a,h]-
anthracene set by Nisbet and LaGoy (1992)
is higher than earlier published values.
Dibenz[a,h]anthracene has a TEF of 5,
which is the ratio with B[a]P in the lower
dose range (appropriate for environmental
exposures), whereas 1 is the ratio for higher
doses. Some “noncarcinogenic PAHs” (flu-
oranthene, phenanthrene, pyrene) have
been assigned TEFs of 0.001 in contrast to
the U.S. EPA TEF scheme where they are
0. The authors claim that assigning a TEF
of 0.001 to the “noncarcinogenic PAHs” is
motivated by their having “some, albeit
limited, carcinogenic activity in some stud-
ies.” However, this factor seems very uncer-
tain, and it should be recognized that even
a low factor becomes important in cases
with high levels.
The observed tumor incidences from
two experimental studies on exposure to
mixtures of PAHs were compared by Nisbet
and LaGoy (1992) to expected incidences
(based on TEFs). The observed and expected
incidences were quite similar except for mix-
tures including noncarcinogenic PAHs, in
which the expected incidences were higher
than those observed. From these compar-
isons, the assumption of additivity seems to
be correct. However, better-designed studies
are needed to conﬁrm this.
In a criteria document on PAHs from
the Netherlands (RIVM 1989), 10 individ-
ual PAH compounds were selected for
evaluation. The carcinogenic potency of the
individual selected PAH compounds was
evaluated on the basis of oral, inhalatory,
intraperitoneal, or dermal animal experi-
ments. The potencies relative to B[a]P are
shown in Table 13. As can be seen by the
ranges in this table, the potencies may differ
strongly depending on the route of adminis-
tration and the target organ. As can also be
seen from Table 13, the TEF values for
phenanthrene and fluoranthene are rela-
tively high compared with the TEFs given
by the U.S. EPA and Nisbet and LaGoy
(0.01 and up to 0.06, respectively, com-
pared with 0 and 0.001). The upper range
of the TEF value for chrysene is also rela-
tively high (0.89) and is based on liver
tumors after intraperitoneal injection.
In a criteria document issued by the
California EPA (CARB 1994), TEF values
were developed for PAHs and PAH deriva-
tives known to be carcinogenic in animals
(see also Collins et al. 1998). For most of
these chemicals, data on mouse skin car-
cinogenesis were used to compare the can-
cer activity relative to B[a]P. For some
compounds, data were also available from
experiments using intrapulmonary adminis-
tration to rats and tests for lung adenomas
in newborn mice. The TEF values
(rounded to a factor of 10) are shown in
Table 13. In contrast to the other lists of
PAHs considered, the California EPA
included four dibenzopyrenes. Dibenzo-
[a,l]pyrene, dibenzo[a,h]pyrene, and
dibenzo[a,i]pyrene were given TEF values
of 10, and dibenzo[a,e]pyrene was given a
TEF value of 1 based on skin tumor
initiation assays in mice and mammary
gland tumors in rats. Dibenzo[a,l]pyrene
was the most potent member of the group
(Cavalieri et al. 1989, 1991).
In a report from Health Canada
(Government of Canada 1994; Meek et al.
1994), ﬁve PAHs classiﬁed as “probably car-
cinogenic to humans” were evaluated based
on a study by Deutsch-Wenzel et al. (1983).
In this study, there were exposure–response
relationships in Osborn-Mendel female rats
administered B[a]P, benzo[b]fluoranthene,
and benzo[j]fluoranthene, and benzo[k]-
fluoranthene, and indeno[1,2,3-cd]pyrene
by lung implantation. Carcinogenic poten-
cies were estimated on the basis of multi-
stage modeling of the tumor incidence to
calculate a TD0.05 value (the dose associated
with a 5% increase in tumors). The poten-
cies relative to B[a]P (TEF values) were
0.06 for benzo[b]fluoranthene, 0.05 for
benzo[j]fluoranthene, 0.04 for benzo[k]-
fluoranthene, and 0.12 for indeno[1,2,3-
cd]pyrene (Table 13). It should be noted,
however, that the relative potency values are
different in the original article by Deutsch-
Wentzel et al. (1983). These authors used a
probit analysis of the results and they
reported the following relative potency val-
ues: 0.19 for anthanthrene; 0.11 for
benzo[b]fluoranthene, 0.03 for benzo[j]flu-
oranthene; 0.03 for benzo[k]fluoranthene;
and 0.08 for indeno[1,2,3-cd]pyrene (data
not shown in Table 13).
The lung implantation study by
Deutsch-Wenzel et al. (1983) was also
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Table 13. Relative potency of individual PAHs compared with B[a]P (TEF values), according to different authors.a
Clement (1986) 
Chu and Chen (cit. Nisbet  Health  Larsen 
(1984) (cit.  and LaGoy Nisbet and The  CARB Canada Ontario and 
Nisbet and  1992); Krewski  LaGoy  Netherlands (1994); Collins  (Meek et  (Muller  Larsen
Compound LaGoy 1992) et al. (1989) (1992)  (RIVM 1989)  et al. (1998)  al. 1994) 1997)  (1998) 
Anthracene 0.01 0 0.0005
Phenanthrene 0.001 0.01 0.00064 0.0005
Benz[a]anthracene 0.013 0.145 0.1 0–0.04 0.1 0.014 0.005
Benzo[c]phenanthrene 0.023 0.023
Chrysene 0.001 0.0044 0.01 0.05–0.89 0.01 0.026 0.03
Fluoranthene 0.001 0–0.06 0.05
Pyrene 0.081 0.001 0 0.001
B[a]P 1 1 1 1 1 1 1 1
Benzo[e]pyrene 0.004 0 0.002
Benzo[b]ﬂuoranthene 0.08 0.14 0.1 0.1 0.06 0.11 0.1
Benzo[j]ﬂuoranthene 0.061 0.1 0.05 0.045 0.05
Benzo[k]ﬂuoranthene 0.04 0.066 0.1 0.03–0.09 0.1 0.04 0.037 0.05
Cyclopenta[cd]pyrene 0.023 0.012 0.02
Dibenzo[a,h]anthracene 0.69 1.11 5 0.89 1.1
Anthanthrene 0.32 0.28 0.3
Benzo[ghi]perylene 0.022 0.01 0.01–0.03 0.012 0.02
Dibenzo[a,e]pyrene 1 1.0b 0.2
Dibenzo[a,h]pyrene 10 1.2 1
Dibenzo[a,i]pyrene 10 0.1
Dibenzo[a,l]pyrene 10 100b 1
Indeno[1,2,3-cd]pyrene 0.017 0.232 0.1 0–0.08 0.1 0.12 0.067 0.1
aSee comments in the text. bData from Muller et al. (1995), cited in WHO/IPCS (1998). used as the main basis for the relative
potency values put forward in a recent
British report (Expert Panel 1999). PAHs
regarded as probably or possibly carcino-
genic were assigned the following TEF val-
ues relative to B[a]P: benz[a]anthracene,
0.1; dibenz[a,h]anthracene, 1.91;
benzo[b]fluoranthene, 0.11; benzo[k]fluo-
ranthene, 0.03; indeno[1,2,3-cd]pyrene,
0.08; and chrysene, 0.03 (data not shown
in Table 13).
Nesnow et al. (1996) have examined
some PAHs for their lung tumorigenic
activities in strain A/J mice. PAHs were
administered by intraperitoneal injection,
and the mice were sacriﬁced after 8 months.
The dose–response data for each PAH were
modeled to obtain potency values relative to
B[a]P (data not shown in Table 13). The
authors also made some comparisons with
earlier relative potencies derived from sub-
cutaneous injection studies and dermal
application in mice. In those studies,
dibenz[a,h]anthracene was as active as
B[a]P, but in the study by Nesnow et al.
(1996), dibenz[a,h]anthracene was 16.5
times more potent than B[a]P in inducing
lung adenomas in mice. Cyclopenta-
[cd]pyrene was as active as B[a]P in induc-
ing lung adenomas in mice (TEF 1.2), but
in earlier skin application studies in mice,
cyclopenta[cd]pyrene was less active than
B[a]P. Benzo[b]ﬂuoranthene was less active
(TEF 0.56) than B[a]P in the strain A/J
mouse lung adenoma system. 
In a Canadian report, prepared for the
Ontario Ministry of Environment and
Energy (Muller 1997), TEF values were
assigned for 209 individual PAHs. The
TEFs are based primarily on tumor initia-
tion in mouse skin. If such data were lack-
ing, data from assays on rat lung or
complete carcinogenicity data from mouse
skin were used. To be able to use data from
different experimental protocols, they were
compared at a standardized time of obser-
vation. The reported TEF values agree rea-
sonably well with those of Nisbet and
LaGoy (1992), except for dibenz-
[a,h]anthracene, which was assigned a value
near 1 (Table 13). Despite the large num-
ber of TEF values, many of the most abun-
dant PAHs in air still lack TEF values. The
vast majority of the Canadian TEFs are for
substituted PAHs not found or analyzed for
in ambient air.
In addition to the 209 TEFs set by
Muller in 1997, TEFs for dibenzo-
[a,e]pyrene and dibenzo[a,l]pyrene were set
to 1 and 100, respectively, by Muller and co-
workers in 1995 according to the WHO/
IPCS document on PAHs (WHO/IPCS
1998). The TEF value of 100 for dibenzo-
[a,l]pyrene is the highest TEF set in any of
the TEF schemes. Some of the TEF schemes
reported here, as well as some other schemes,
are listed in the WHO/IPCS document
(WHO/IPCS 1998).
In a recent review of chemical carcino-
gens in air, Larsen and Larsen (1998) listed
estimates of the carcinogenic potencies of
various PAHs relative to B[a]P (Table 13).
This TEF scheme is based on the extensive
database on carcinogenicity studies using
various routes of administration. The TEF
values are quite similar to other schemes,
such as those of Nisbet and LaGoy (1992).
However, the TEF for fluoranthene is 0.05
compared with 0.001, which makes quite a
difference, as fluoranthene occurs at rela-
tively high levels in ambient air. In addi-
tion, anthracene and benz[a]anthracene are
assigned lower TEF values by Larsen and
Larsen (0.0005 and 0.005, respectively)
than by Nisbet and LaGoy (0.01 and 0.1,
respectively).
Fluoranthene as an indicator.
Fluoranthene is interesting because of its
occurrence at relatively high concentrations
in the environment. According to Swedish
measurements (see “Sources, Deposition,
and Ambient Concentrations”), fluoran-
thene is present at approximately 10 times
higher levels than B[a]P in ambient air, in
gasoline exhausts (from engines with cat-
alytic converters), and in emissions from
wood combustion. In emissions from
domestic oil heating, the levels of fluoran-
thene are approximately 30 times higher
than those of B[a]P, but they are more
than 100 times higher in emissions from
modern diesel engines (Tables 5 and 8). In
contrast, the emissions from coke-oven
plants contain concentrations of fluoran-
thene around 3 times higher than B[a]P
(IARC 1984b).
Fluoranthene is mutagenic but not clas-
sified as a carcinogen by IARC (based on
dermal application studies). However,
according to the WHO/IPCS document
(WHO/IPCS 1998), a limited number of
more recent studies with intraperitoneal
administration to newborn mice show that
ﬂuoranthene is an experimental carcinogen.
Fluoranthene caused lung and liver tumors
after 12 months in a study by LaVoie et al.
(1994). Because B[a]P was also tested in the
same study, a TEF value can be calculated.
The B[a]P dose and the high dose of fluo-
ranthene gave approximately the same tumor
frequency and the resulting TEF value
would thus be 0.08. As mentioned above,
the TEF assigned by Larsen and Larsen
(1998) is 0.05 (Table 13).
Because of its abundance in emissions
from combustion, ﬂuoranthene might be an
important contributor to the risk from PAH
exposure.
Combination of Toxic Equivalency
Factor Values and Concentrations 
of PAHs in Air: Examples from
Different Countries
In the choice of indicator substances for
carcinogenic PAHs, the relative cancer
potency as well as the relative concentration
of individual compounds found in different
emissions and in ambient air are important.
In several countries measured concentra-
tions along with assigned TEF values (Table
13), have been used to estimate the relative
contribution of individual PAH compounds
to the added total carcinogenicity of the
measured PAHs in ambient air. Obviously,
the results of such calculations depend on
several factors such as the number of PAH
compounds considered, whether both par-
ticulate and volatile PAHs are included,
how representative the sampling is, and of
course, the assigned TEF values. Additivity
is assumed in these calculations; however,
whether this assumption is appropriate/cor-
rect has yet to be demonstrated. The exam-
ples given below illustrate different
outcomes depending on the assumptions
that were made.
The Netherlands. In the Dutch criteria
document from RIVM (1989), a subset con-
sisting of at least two PAHs per ring class
was selected. The following 10 compounds
were selected for evaluation: naphthalene,
anthracene, phenanthrene, fluoranthene,
benz[a]anthracene, chrysene, benzo[a]fluo-
ranthene, B[a]P, benzo[ghi]perylene, and
indeno[1,2,3-cd]pyrene. The selection was
based on a number of criteria, such as con-
nection with internationally used PAH lists,
the analytic selectivity, recovery and ﬂuores-
cence susceptibility during the determina-
tion, the carcinogenicity of the compound,
and the relation of the PAH list to emission
proﬁles of sources. The ranges of TEF values
discussed are shown in Table 13. The aver-
age concentrations of the selected PAH com-
pounds in urban and rural air were
multiplied by the upper range of the TEF
values to obtain the concentrations expressed
as B[a]P equivalents. Both particles and
volatile PAHs were sampled. In these calcu-
lations, phenanthrene, fluoranthene, and
chrysene contributed more than B[a]P to the
sum of B[a]P equivalents from the 10 PAHs
as a result of their relatively high assigned
TEF values in combination with their rela-
tively high concentrations.
Switzerland. In an article by Petry et al.
(1996) the concentrations of 14 selected
PAHs were measured on two occasions in a
Swiss city. Only particle-bound PAHs were
analyzed. The individual PAHs were assigned
the TEF values proposed by Nisbet and
LaGoy (1992), and the relative contribution
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calculated. According to these calculations,
B[a]P contributed 65 and 58% to the sum of
the B[a]P equivalents. Benzo[b]ﬂuoranthene,
benzo[j]ﬂuoranthene, benzo[k]ﬂuoranthene,
indeno[1,2,3-cd]pyrene, and dibenz[a,h]-
anthracene contributed about 10% each.
Compared with the calculations from the
Netherlands, much lower TEF values were
used for phenanthrene, fluoranthene, and
chrysene. Consequently, these PAHs con-
tributed much less to the total carcinogenic-
ity, which was further accentuated by the
fact that only particle-bound PAHs were
measured. Phenanthrene and fluoranthene
are relatively volatile PAHs. Petry and
co-workers (1996) also made similar calcula-
tions for some occupational exposures (coke,
anode, graphite, silicon carbide, metal-
recycling plants, and bitumen paving), but in
this case both gaseous and particulate PAHs
were measured by personal monitoring. In
these occupational settings, B[a]P con-
tributed 27–67% of the total carcinogenicity
of the PAHs considered. The authors con-
cluded that B[a]P is a good marker for these
different PAH mixtures.
United Kingdom. When the mean con-
centrations of seven selected carcinogenic
PAHs (particulate and vapor phase) in ambi-
ent air (London and Middlesborough) and
in an aluminum smelter workplace were
multiplied by their assigned TEF values, the
contributions of B[a]P to the sum of the
B[a]P equivalents were 45, 38, and 49% in
London, Middlesborough, and the alu-
minum smelter, respectively. The PAH com-
pounds were the following: B[a]P,
benz[a]anthracene, dibenz[a,h]anthracene,
benzo[b]ﬂuoranthene, benzo[k]ﬂuoranthene,
indeno[1,2,3-cd]pyrene, and chrysene
(Expert Panel 1999). 
France. Personal exposure to particulate-
phase atmospheric PAH was assessed in
Grenoble for 48 hr (Zmirou et al. 2000).
The measured PAHs were B[a]P,
benz[a]anthracene, benzo[b]fluoranthene,
benzo[k]fluoranthene, indeno[1,2,3-
cd]pyrene, benzo[ghi]perylene, chrysene, ﬂu-
oranthene, and pyrene. When the TEF
values by Nisbet and LaGoy (1992) (Table
13) were applied to the measured concentra-
tions, about two-thirds of the total cancer
risk was related to B[a]P, and the second
most influential compound was indenopy-
rene. Although fluoranthene was measured
at a concentration 10 times higher than
B[a]P, the low TEF value used (0.001) had a
small inﬂuence on the total carcinogenicity.
Canada. The Canadian risk assessment
of PAHs (Government of Canada 1994;
Meek et al. 1994) is based on the carcino-
genicity of ﬁve PAHs classiﬁed as “probably
carcinogenic to humans,” namely, B[a]P,
benzo[b]fluoranthene, benzo[j]fluor-
anthene,  benzo[k]fluoranthene, and
indeno[1,2,3-cd]pyrene. The carcinogenic
potencies of these PAHs relative to B[a]P
are shown in Table 13. The concentrations
of these PAHs in different localities in
Canada (particles and volatiles) were com-
bined with the corresponding TEF values,
and the relative contributions from these
PAHs in ambient air (in B[a]P equivalents)
show that B[a]P contributes more than the
other selected PAHs (70–100% of the
carcinogenic activity).
The State of California, USA. The Air
Resources Board of the California
Environmental Protection Agency has pre-
pared a health risk assessment of B[a]P as a
toxic air contaminant (CARB 1994). B[a]P
was chosen as representative of PAHs
because it is the best-investigated individual
PAH compound. The statewide population-
weighted exposure to B[a]P in California
was estimated to be 0.53 ng/m3 (only parti-
cle-associated PAHs). Based on the ambient
concentrations and potency equivalency
factors (TEFs, see Table 13) for benzo[b]-
fluoranthene, benzo[k]fluoranthene,
indeno[1,2,3-cd]pyrene, and dibenz[a,h]-
anthracene, the combined risk from expo-
sure to these four PAHs was calculated to be
approximately one-third that of B[a]P. 
In an article by Collins et al. (1998), the
California TEF values for those nine PAHs
considered to be carcinogenic (Table 13)
were applied to measured concentrations of
particle-bound PAHs in Riverside,
California. In contrast to the data from other
countries, dibenzopyrenes were also mea-
sured. Because of the high TEF value
assigned to dibenzo[a,l]pyrene, this individ-
ual PAH compound made the greatest con-
tribution to the carcinogenicity (5 times that
of B[a]P). B[a]P, benzo[b]fluoranthene,
benzo[j]fluoranthene, and benzo[k]fluor-
anthene contributed equally. In this article
some nitro-PAHs were also considered
(1- and 4-nitropyrene, 2-nitrofluoranthene,
1,6-dinitropyrene, 6-nitrochrysene, and 2-
nitrofluorene). However, the total carcino-
genic activity of these compounds was
insignificant compared with that of B[a]P,
benzoﬂuoranthenes, indeno[1,2,3-cd]pyrene,
and dibenzo[a,l]pyrene.
Sweden. To be able to discuss which
individual PAHs are most important from a
Swedish perspective, B[a]P equivalents were
calculated for ambient air [in the center of
Stockholm and at a background station,
Rörvik, situated at the west coast of Sweden
(Table 14)], emissions from gasoline and
diesel engines (Table 15), and emissions
from domestic wood and oil heating (Table
16). The TEF scheme by Larsen and Larsen
(1998) was used for two reasons: it takes
into account the most recent data, and the
TEFs for fluoranthene agree well with the
latest reports on the carcinogenic potential
of fluoranthene (see “Fluoranthene as an
indicator”). It should be noted that the per-
centage values given in Tables 14–16 are
dependent on the number and the individ-
ual PAHs analyzed, and they should not be
regarded as true values.
In the ambient air, it is obvious that out
of the analyzed PAHs that have been
assigned TEFs, B[a]P and fluoranthene
contribute most to the B[a]P equivalents
(Table 14). B[a]P accounts for 58 and 50%
of total B[a]P equivalents in Stockholm and
Rörvik, respectively, whereas fluoranthene
contributes 21 and 26%, respectively.
Benzofluoranthenes and indeno[1,2,3-
cd]pyrene also contribute more than 5% of
the total B[a]P equivalents.
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Table 14. PAH concentrations, B[a]P equivalents, and percentage contribution of 11 PAHs to the B[a]P
equivalents calculated for ambient aira in Stockholmb and Rörvik.c
Stockholm (1997)  Rörvik (1994)
Conc. B[a]P eq. B[a]P Conc. B[a]P eq. B[a]P eq.
PAH TEFd (ng/m3) (ng/m3) (%) (ng/m3) (ng/m3) (%)
Anthracene 0.0005 12.6 0.0063 0.2 0.044 0.000022 0.02
Benz[a]anthracene 0.005 1.7 0.0085 0.3 0.065 0.00033 0.2
B[a]P 1.0 1.7 1.7 58 0.072 0.072 50
Benzo[b]ﬂuoranthene 0.1 3.6e 0.27e 9.3e 0.17 0.017 12
Benzo[k]ﬂuoranthene 0.05 0.074 0.0037 2.5
Benzo[ghi]perylene 0.02 3.6 0.072 2.5 0.079 0.0016 1.1
Chrysene 0.03 2.1 0.063 2.2 0.15 0.0045 3.1
Fluoranthene 0.05 12 0.6 21 0.76 0.038 26
Indeno[1,2,3-cd]pyrene 0.1 1.6 0.16 5.5 0.075 0.0075 5.2
Phenanthrene 0.0005 30 0.015 0.5 1.2 0.0006 0.4
Pyrene 0.001 18 0.018 0.6 0.21 0.00021 0.1
Total (of 11) 2.9 100 0.15 100
Dibenz[a,h]anthracene 1.1  0.1  0.11  3.8f
aNote that the sum is calculated for the given PAH only, although there are other PAHs present in the ambient air that
might also contribute to the carcinogenic risk. bData from Burman (2001). cData from Brorström-Lunden et al. (2000).
dData from Larsen and Larsen (1998). eReported as benzoﬂuoranthene. A TEF value of 0.075 has been used. fThis PAH is
not included in the total above.For emissions from gasoline and diesel
engines, B[a]P and ﬂuoranthene are also the
major contributors to total B[a]P equivalents
(Table 15). However, it should be noted
that fluoranthene alone accounts for the
greatest part (85–88%) in diesel emissions,
whereas B[a]P contributes more than fluo-
ranthene in gasoline emissions. 
B[a]P and fluoranthene are also the
major contributors to the B[a]P equivalents
of emissions from domestic wood and oil
heating, together representing 92 and 88%,
respectively (Table 16). In emissions from
wood burning, B[a]P contributes slightly
more than fluoranthene, and vice versa for
emissions from domestic oil heating. In the
emissions from domestic oil heating, phenan-
threne is also an important contributor.
The results of the calculations of total
B[a]P equivalents for ambient air using the
TEFs by Larsen and Larsen (1998) agree
well with the results obtained with the TEF
scheme by Nisbet and LaGoy (1992),
although the individual TEF values vary
considerably. The TEF scheme by RIVM
(1989) leads to B[a]P equivalents that differ
most from the other schemes. Generally, the
RIVM TEFs result in comparably higher
B[a]P equivalents for chrysene and phenan-
threne, whereas B[a]P, indeno[1,2,3-
cd]pyrene, and benzoﬂuoranthenes get lower
B[a]P equivalents (data not shown). A prob-
lem with the RIVM TEFs is that the TEFs
are given as ranges in most cases. The upper
range is used in the calculations, although
the scientiﬁc validity of this is questionable.
Summary and Conclusions
Epidemiologic data have demonstrated that
occupational exposure to soot, coal tar, and
other PAH-containing mixtures is carcino-
genic to humans. The increased risk for
lung cancer in coke-oven workers has been
used for quantitative risk estimates with the
content of B[a]P as indicator substance.
The WHO unit risk estimate for humans is
8.7 × 10–5 per ng/m3 B[a]P as indicator. A
similar risk estimate can be derived from
the increased risk for lung cancer in
aluminum smelters.
In an inhalation study with hamsters,
B[a]P induced tumors in the nasopharyn-
geal tract and the trachea but not in the
lung. This study has been used for quantita-
tive risk estimates, but because of various
deficiencies in the study, the quantitative
estimate must be regarded as very uncertain.
The lifetime unit risk estimate for humans,
based on this study, is reported as 0.3–1.7 ×
10–6 per ng/m3. Calculations based on
intratracheal administration in hamsters led
to a risk of 3.3–4.8 × 10–6 per ng/m3. A
more recent study with rats inhaling a coal
tar/pitch aerosol led to a risk for lung
tumors of 20 × 10–6 per ng/m3 B[a]P as
indicator of the PAH mixture.
In principle, the cancer risk assessment
of PAHs in ambient air can be performed in
two ways. One approach is to add the risks
from selected individual PAH compounds as
determined from animal experiments. The
other approach is to use B[a]P as an indica-
tor of the mixture of carcinogenic PAHs in
air and apply that to the dose–response rela-
tionship observed in epidemiologic studies.
Both of these approaches have considerable
weaknesses. WHO has chosen epidemiologic
data on coke-oven workers for risk assess-
ment in the Air Quality Guidelines for
Europe (WHO 1987, 2000).
Several authors have calculated the rela-
tive potency of different PAHs compared
with the potency of B[a]P in bioassays such
as the skin application tumor assay in mice,
or other cancer tests. The TEF value of
B[a]P is set to 1. In almost all of the pub-
lished rankings, the TEF value for most
other PAHs is less than 1, except for
dibenz[a,h]anthracene, which was given
TEF values higher than 1 by some authors.
The dibenzopyrenes were considered in the
California EPA document (CARB 1994), as
well as by Muller in 1997 and Larsen and
Larsen in 1998, and the ah, ai, and al iso-
mers were assigned TEF values of 0.1–100.
Phenanthrene, pyrene, anthracene, and ﬂuo-
ranthene, which occur at relatively high con-
centrations in ambient air but are generally
not considered to be carcinogenic, have been
assigned low but varying TEF values by
some authors but not by others. However,
fluoranthene is an experimental carcinogen
in a speciﬁc test system, and in a recent TEF
scheme, ﬂuoranthene was assigned a higher
TEF value (0.05) (Larsen and Larsen 1998).
TEF values for a few selected carcino-
genic PAHs, together with their estimated
concentrations in ambient air, indicated
B[a]P as the dominating contributor to the
carcinogenicity of these PAHs in England,
California, and Canada. In a more recent
California article (Collins et al. 1998),
dibenzopyrenes were also measured. This
study indicated dibenzo[a,l]pyrene as the
main contributor to the carcinogenicity.
Similar calculations in the Netherlands also
included some PAHs not generally consid-
ered carcinogenic. Because of their relatively
high concentrations in ambient air and
assigned TEF values of 0.01, 0.06, and
0.89, respectively, phenanthrene, fluoran-
thene, and chrysene contributed more than
B[a]P to the carcinogenicity in the Dutch
calculations. In calculations on Swedish
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Table 16. The relative contribution of individual
PAHs to B[a]P equivalents calculated for emis-
sionsa from domestic burning of wood and oil.b
PAH TEFc Wood Oil
% the of total 
B[a]P equivalents
Anthracene 0.0005 0.3 0.2
Benz[a]anthracene 0.005 1.0 0.2d
B[a]P 1 53 35d
Benzo[b and k]- 0.075 2.8 2.6d
ﬂuoranthene
Benzo[ghi]perylene 0.02 0.3 ND
Chrysene/triphenylene 0.03e ND 1.1d
Fluoranthene 0.05 39 53
Indeno[1,2,3-cd]pyrene 0.1 1.6 ND
Phenanthrene 0.0005 1.8 7.6
Pyrene 0.001 0.6 0.2
Total (µg/MJ) 19 0.0085
ND, not determined. aNote that the sum is calculated for
the given individual PAH only, although there are other
PAHs present in the emissions that might also contribute
to the carcinogenic risk of the emissions. bFor concen-
trations of individual PAHs, see Table 8. cData from
Larsen and Larsen 1998. dConcentration below the detec-
tion limit. The detection limit is used for calculations.
eTEF for chrysene.
Table 15. The relative contribution of individual PAHsa to B[a]P equivalents calculated for emissions from
gasoline and diesel engines.b
Light-duty vehicles Heavy-duty trucks
Gasoline Gasoline Diesel light  Diesel  Diesel (MK1) 
without +  three-way  (MK1) + oxidizing (MK3) without without 
catalytic catalytic  catalytic catalytic catalytic 
PAH TEFc converter converter converter converter  converter
% of total B[a]P equivalents
Anthracene 0.0005 0.2 0.4 0.1 0.3 0.1
Benz[a]anthracene 0.005 0.2 0.3 0.1 0.4 d,e
B[a]P 1 77 43 5.3 4.2 7.1d
Benzo[b and k]ﬂuoranthene 0.075 4.4 11 1.6 0.8 0.5d
Benzo[ghi]perylene 0.02 1.4 1.4 0.2 d,e 0.1d
Chrysene/triphenylene 0.03f 1.4 4.3 1.6 0.6 0.4
Fluoranthene 0.05 12 36 88 86 85
Indeno[1,2,3-cd]pyrene 0.1 2.3 1.4 0.5 0.2d 0.7d
Phenanthrene 0.0005 0.5 2.0 1.0 2.8 1.4
Pyrene 0.001 0.3 0.4 1.3 4.4 4.9
Total (µg/km) 8.6 0.7 1.9 4.8 1.4
aNote that the sum is calculated for the given individual PAH only, although there are other PAHs present in the emis-
sions that might also contribute to the carcinogenic risk of the emissions. bFor concentrations of individual PAHs, see
Table 5. cData from Larsen and Larsen 1998. dConcentration below the detection limit. The detection limit is used for cal-
culations. eBelow 0.1%. fTEF for chrysene.ambient air and emissions from diesel and
gasoline vehicles and domestic wood and oil
heating, B[a]P together with fluoranthene
was the major contributor to the carcino-
genicity. B[a]P was the most important
PAH in ambient air, gasoline exhausts, and
emissions from wood burning, whereas ﬂuo-
ranthene was the dominating PAH in diesel
exhausts and emissions from oil heating.
These calculations support the use of B[a]P
as an indicator of carcinogenic PAHs in
ambient air.
Although B[a]P is a good indicator of
carcinogenic compounds in coke-oven emis-
sions and other PAH-rich emissions, its ade-
quacy as indicator of carcinogenic ambient
air pollutants has been questioned. For
example, it has been shown that the potency
of cigarette smoke and diesel exhaust that
contain large amounts of carcinogenic com-
pounds other than PAHs is much higher at a
given level of B[a]P than coke-oven emis-
sions, which derive much of their carcino-
genicity from unsubstituted four- to
seven-ring PAHs. Nevertheless, of a number
of selected PAH compounds, B[a]P has been
estimated to be a dominating contributor to
the carcinogenicity both in ambient air and
in different occupational settings, and it
should still be regarded as a relevant indica-
tor of carcinogenic airborne PAHs. This also
lends some credit to the WHO risk estimate,
which is based on epidemiology with B[a]P
as an indicator, although the PAH proﬁle in
ambient air is not identical to that in coke-
oven emissions.
Considering the TEF values presented
in Table 13 together with their calculated
relative contribution to the carcinogenicity
of ambient air in Sweden (Table 14), the
following PAHs can be recommended as
indicators: B[a]P, benzofluoranthenes,
dibenz[a,h]anthracene, dibenzo[a,l]pyrene,
ﬂuoranthene, and indeno[1,2,3-cd]pyrene.
However, it should be noted that the rel-
ative order of PAH potency might not be
the same for the inhalation route as for the
different routes of exposure that formed the
basis for establishment of the TEF values. 
One disadvantage of using B[a]P as sur-
rogate for the PAH mixture in ambient air is
that substituted PAHs are not well repre-
sented by B[a]P and they must be consid-
ered separately. Nevertheless, when some
nitro-PAHs were considered in calculations
from California, their relative contribution
to the carcinogenicity of ambient air was
minor compared with that of dibenzo-
[a,l]pyrene, B[a]P, and benzoﬂuoranthenes.
Summary and Conclusions
Polycyclic aromatic hydrocarbons (PAHs)
are important air pollutants. Some of the
individual PAHs are known carcinogens,
and the group as a whole is regarded as
carcinogenic. Historically, B[a]P has been
used as an indicator of carcinogenic PAHs,
although the relevance for today’s air pollu-
tion pattern has been questioned in view of
a change in emission profiles of modern
diesel engines and fuels. The aim of the
present study was to discuss the suitability
of possible indicators and to devise propos-
als for both indicator substances and guide-
line values. The intention has been to
highlight certain mechanistic aspects of the
carcinogenicity of PAHs and of risk assess-
ment, with the focus on comparative quan-
titative potency of different PAHs. The
relative carcinogenic activity of individual
PAHs together with the concentrations
found in ambient air have been important
selection criteria for the choice of indicator
substances. The following summary is
based on the preceding sections of this doc-
ument, and the reader is referred to those
for literature references.
Emissions and Concentrations
PAHs constitute a wide class of compounds
with fused aromatic rings. PAHs are formed
in incomplete combustion processes, and it
has been known for a long time that expo-
sure to soot, coal tar, and pitch entails an
increased risk for tumor development in
humans. IARC has also classified several
other PAH-containing complex mixtures as
carcinogenic to humans (e.g., occupational
exposures in aluminum production, coal
gasification, and coke production) or as
probably carcinogenic to humans (e.g., cre-
osotes, diesel exhausts). Individual PAH
compounds have been tested in skin-paint-
ing assays and other animal experiments, and
many have demonstrated carcinogenic
effects. In this report we restrict the discus-
sion mainly to unsubstituted PAHs,
although the compounds may exist in substi-
tuted form (i.e., alkyl-, nitro-, amino-, or
halogen-substituted PAHs). PAHs also par-
ticipate in atmospheric chemical reactions,
leading to the formation of more polar and
more water-soluble PAH derivatives such as
hydroxylated, oxygenated, or nitrated PAHs.
The atmospheric half-life of PAHs is on the
order of a few hours to a few days.
The data on emissions of PAHs are
uncertain, but there has been a substantial
reduction in emissions since 1960. However,
more regular measurements during the last
decade at a background station at Rörvik at
the west coast of Sweden and at Hornsgatan
in the center of Stockholm (see
“Concentrations in Ambient Air”) have not
shown any deﬁnite trends in the air concen-
trations. Today, wood burning is believed to
be the major source of PAH emissions to air
in Sweden, producing about 60% of the
total emissions, whereas traffic contributes
about 30%. Old passenger cars without cat-
alytic converters and diesel vehicles with
older combustion technology contribute
most of the traffic-related emissions of
PAHs. Cold starts of petrol-driven vehicles
are an important contributing factor for
PAH emissions. 
PAH emission proﬁles are not speciﬁc to
each source but rather reflect efficiency in
combustion and fuel quality in general.
Diesel exhaust, however, is characterized by
PAHs with a lower molecular mass, whereas
wood burning and petrol cars without cat-
alytic converters emit a larger fraction of
heavy multiringed PAHs compared with
diesel exhaust. Modern diesel engines using
environmentally classified diesel fuel and
modern catalyst-equipped petrol cars emit
only minute amounts of heavy PAHs such
as B[a]P.
Total PAH levels of ambient air from
different measurements are often difﬁcult to
compare, as different individual PAHs have
been measured. In Europe, B[a]P concentra-
tions are often below 1 ng/m3 at background
stations, whereas at locations close to trafﬁc,
concentrations range between 1 and 5
ng/m3. At the street-level site in the center of
Stockholm (Hornsgatan), the sum of 14
PAHs ranges from 100 to 200 ng/m3. The
B[a]P levels vary between 1 and 2 ng/m3.
The most abundant PAH is phenanthrene,
which constitutes about one-third of the
total amount.
Carcinogenicity of PAHs
The carcinogenic activity of PAHs is consid-
ered to be the critical effect, although animal
experiments indicate that such compounds
may also give rise, for example, to immuno-
logic and reproductive effects. In this docu-
ment we focus on the carcinogenicity.
Several PAHs are considered complete car-
cinogens, and thus they may act at different
stages in the carcinogenic process at both the
genotoxic and nongenotoxic levels.
Interaction of the parent PAH compound
with the so-called Ah receptor may induce
enzymes participating in the metabolism and
subsequent increases in genotoxic metabo-
lites. Another effect of Ah receptor binding
may be on the level of cell proliferation and
differentiation. Ah receptor binding is thus
one of the mechanisms contributing to the
carcinogenicity of PAHs. Other mechanisms
may include the initiation of inflammatory
processes and stimulated oxidative stress.
The mutagenic and carcinogenic activity
of PAHs requires metabolic activation to
reactive intermediates (mainly DEs) and
their subsequent covalent binding to critical
targets in DNA. The mutagenic and car-
cinogenic activity of a PAH is associated
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lar mass of the molecule; a more complex
compound is usually more potent.
Recognized carcinogenic unsubstituted
PAHs belong to the class of four- to seven-
ring members. Factors likely to inﬂuence an
individual’s susceptibility toward PAH
exposure include polymorphisms in genes
encoding enzymes participating in the
metabolism of the PAHs (e.g., activating
cytochromes P450 and detoxifying GSTs).
Metabolism of PAHs occurs mainly in the
liver. However, inhalation is the main route
of exposure to PAHs in ambient air; conse-
quently, metabolism in lung tissue also has
to be considered. Because of the lipophilic
properties of PAHs, a fraction of the com-
pounds is likely to be retained in the lung
tissue and to attain high local concentra-
tions. Despite the rather modest metabolic
capacity of lung tissue, local activation and
formation of active metabolites in the air-
way epithelium may be of importance in
specific parts of the lungs, such as the
bronchial epithelium.
In human biomonitoring of PAH expo-
sure, blood cells are frequently employed,
and protein and/or DNA adducts estimated
as a measure of overall exposure. The intake
of PAHs is generally higher by food than by
inhalation. Determination of DNAs or pro-
tein adducts of PAHs has been considered a
suitable way of estimating the systemic
internal dose to humans. There are still
problems with regard to the sensitivity,
specificity, and the stability of different
adducts that render such methods less suit-
able at present for use in routine biological
monitoring. Determination of hydroxylated
metabolites in urine, derived from pyrene
and phenanthrene, can be used for monitor-
ing exposure to environmental PAHs.
Quantitative Risk Estimates
Estimates derived from human data.
Quantitative cancer risk estimates of PAHs
as air pollutants are uncertain because of lack
of useful, good-quality data in addition to
the complexity of the problem. Although
several epidemiologic studies indicate that
urban air pollution is a risk factor for lung
cancer, these studies do not generally pro-
vide a quantitative correlation to estimated
PAH levels. Cigarette smoke obviously con-
tains many other strongly carcinogenic com-
pounds besides PAHs, which renders
cigarette smoke less suitable as a basis for risk
assessment of PAH exposure. Diesel exhaust
is an important source of PAHs in ambient
air, but the epidemiologic studies on diesel
exhausts and lung cancer have not yet pro-
vided any quantitative risk estimates in rela-
tion to PAHs. Diesel exhaust also contains
nitro-PAHs and other carcinogenic
substances besides pure PAH. There are no
epidemiologic data concerning wood com-
bustion. Accordingly, it is still necessary to
use earlier studies on coke-oven emissions to
assess the human risk to PAH exposure, as
coke-oven emissions have clearly been associ-
ated with an increased risk for lung cancer,
also in quantitative terms. One difﬁculty in
comparing different exposures is that the
PAH proﬁles may differ.
At the present stage of knowledge, risk
estimation of PAHs at low exposure levels
should be based on the assumption of linear
dose–response relationships. In the WHO
Air Quality Guidelines for Europe, the risk
assessment is based on lung cancer in coke-
oven workers, with the underlying assump-
tion that any differences in the PAH proﬁles
in coke-oven emissions and ambient air are
not too big to prevent such an extrapolation.
The WHO unit risk estimate for humans is
9 × 10–5 per ng/m3 B[a]P as an indicator.
This risk thus refers to the total PAH mix-
ture and not only to the content of B[a]P. A
risk assessment based on lung cancer in
aluminum-production workers would lead
to a very similar estimate. 
The epidemiologic approach for risk
assessment has also been used in national
risk assessment for PAH compounds in the
Netherlands. In a recent document from
Ontario, Canada, the epidemiologically
based risk assessment for PAHs is recom-
mended. On the other hand, the available
epidemiologic data were considered inade-
quate for risk assessment by Health Canada.
The U.S. EPA formerly used a quantitative
risk estimate for B[a]P based on a hamster
inhalation study, but because of the inade-
quacy of this study, the U.S. EPA does not
currently have an ofﬁcial inhalation risk esti-
mate for B[a]P (or PAHs) in ambient air.
Estimates derived from studies on
rodents. Only one single PAH, B[a]P, has
been tested in animal inhalation studies. In
the most-cited study, tumors were induced
in the nasopharyngeal tract and the trachea
of hamsters but not in the lung. This study
has been used for quantitative risk estimates,
but because of various deficiencies in the
study, the quantitative estimate must be
regarded as very uncertain. The lifetime unit
risk estimate for humans, based on this
study, has been reported as 0.3–1.7 × 10–6
per ng/m3, using different assumptions.
An alternative approach to risk assess-
ment of PAHs in ambient air might be to
add the risks from selected individual PAH
compounds as determined from animal
experiments. In this case, the potencies of
the individual compounds are expressed rela-
tive to the potency of B[a]P as TEF values.
However, ambient air contains many more
PAH compounds than have been investi-
gated experimentally, and only a limited
number of PAHs are usually measured.
Thus, important contributors to the overall
carcinogenic risk may be overlooked. In
addition, because of the high exposure levels
in the animal carcinogenicity studies, the
results may mainly reﬂect the PAH promo-
tive effects. In conclusion, quantitative risk
assessment of PAHs in ambient air, based on
animal experiments, must be regarded with
caution because of such shortcomings.
Indicators according to toxic equivalency
considerations. In all published rankings of
PAHs, B[a]P has been used as the reference
substance. Only a few compounds, such as
some dibenzopyrenes and dibenz[a,h]-
anthracene, are regarded as more potent
than B[a]P. Thus, B[a]P should be regarded
as an essential indicator of carcinogenic com-
pounds in ambient air. However, other
PAHs such as phenanthrene, pyrene, fluo-
ranthene, and various methylated PAHs are
found in higher concentrations in ambient
air. By multiplying the concentration of
individual PAHs with their cancer potency
relative to B[a]P (TEF value), the carcino-
genic activity can be calculated as B[a]P
equivalents. Depending on how many and
which compounds are considered, the rela-
tive contribution from B[a]P and other
selected PAHs to the carcinogenicity of these
PAHs in ambient air may vary. For example,
TEF values for a few selected carcinogenic
PAHs, together with their estimated concen-
tration in air, indicated B[a]P as the domi-
nating contributor to the sum of the B[a]P
equivalents from these PAHs in England,
France, California, and Canada. In a more
recent California study, dibenzopyrenes were
also measured. This study indicated
dibenzo[a,l]pyrene as the main contributor
to the B[a]P equivalents. Similar calculations
(not including dibenzopyrenes) in the
Netherlands and in Switzerland also
included some PAHs, such as phenanthrene,
pyrene, fluoranthene, and various methy-
lated PAHs, that are not generally consid-
ered carcinogenic. In the Dutch calculations,
phenanthrene, fluoranthene, and chrysene
were assigned relatively high TEF values;
because of their high concentrations in
ambient air, these PAHs together con-
tributed more than B[a]P to the B[a]P
equivalents. In the Swiss calculations, the
corresponding TEF values were less than
one-tenth of the Dutch figure, and B[a]P
became the dominating contributor, also
partly because only particle-bound PAHs
were measured.
PAHs as carcinogens in ambient air in
Sweden. Of 11 PAHs considered in Swedish
ambient air at the center of Stockholm and
at a background station (Rörvik), B[a]P and
ﬂuoranthene contributed most to the B[a]P
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the total B[a]P equivalents, whereas ﬂuoran-
thene contributed 21–26%. Benzo-
fluoranthenes and indeno[1,2,3-cd]pyrene
also contribute more than 5% of the total
B[a]P equivalents. B[a]P and fluoranthene
are the major contributors to the total B[a]P
equivalents for emissions from petrol and
diesel engines also. However, it should be
noted that fluoranthene alone accounts for
the major part (85–88%) in diesel emissions,
whereas B[a]P contributes more than fluo-
ranthene in petrol emissions. B[a]P and ﬂuo-
ranthene are also the major contributors to
the B[a]P equivalents of emissions from
domestic wood and oil heating. In emissions
from wood burning, B[a]P contributes
slightly more than fluoranthene, although
the reverse is true for emissions from domes-
tic oil heating. In the emissions from domes-
tic oil heating, phenanthrene is also an
important contributor. In these calculations,
ﬂuoranthene was assigned the relatively high
TEF value of 0.05, which is based on studies
with intraperitoneal exposure in newborn
mice. Contrary to earlier studies with dermal
exposure, ﬂuoranthene was an experimental
carcinogen in these later studies.
It is striking that several of the most
abundant PAHs in ambient air (see
“Sources, Deposition, and Ambient
Concentration” and Table 13) apparently
have not been studied experimentally; conse-
quently, they have not been assigned TEF
values. Furthermore, some of the most car-
cinogenic PAHs, such as dibenzopyrenes, are
not usually analyzed.
Conclusions concerning quantitative risk
estimates. All the cited risk estimates are
uncertain because of various deficiencies in
the database. We do not recommend the use
of experimental animal data on single PAH
substances for purposes other than relative
potency rankings. The epidemiologic data
on lung cancer in coke-oven workers are still
the best basis for a quantitative risk estimate,
and we accept the unit risk estimate in the
WHO Air Quality Guidelines for Europe
(9 × 10–5 per ng/m3 B[a]P as an indicator of
the total PAH mixture). One concern with
the validity of this estimate is a possible dif-
ference in PAH proﬁles between coke-oven
emissions and ambient air. However, the
fact that B[a]P is a major contributor to the
added carcinogenicity of selected PAH com-
pounds in studies on relative potency rank-
ings, combined with actual measured
concentrations in ambient air, supports the
WHO approach using B[a]P as an indicator.
Recommended Indicators of PAHs 
in Ambient Air
Air quality considerations. According to
the section “Sources, Deposition, and
Ambient Concentrations,” the following
PAHs were considered the most represen-
tative, based on qualitative and quantita-
tive properties of emissions and also with
regard to their presence in ambient air:
phenanthrene, methylanthracenes/phenan-
threnes, fluoranthene, pyrene, B[a]P,
benzo[b]fluoranthene, benzo[k]fluoran-
thene, indeno[1,2,3-cd]pyrene, and
benzo[ghi]perylene. In addition, com-
pounds such as dibenzothiophene and
benzonaphthothiophene might be useful
indicators of fuels containing sulfur, such
as exhausts from heavy diesel vehicles, and
retene might be useful as a marker for
wood burning. 
PAHs should be measured in both par-
ticulate and gas-phase samples from ambient
air. The sampling mode and analytic tech-
niques should be harmonized. From the
health point of view, PAHs of all particle
sizes are interesting.
Exhausts from modern diesel engines
and fuels contain comparatively less of the
high-molecular PAHs than older diesel
engines, gasoline vehicles, or emissions from
space heating. As this trend may be accentu-
ated in the future, the relative importance of
volatile PAHs in ambient air may increase.
Thus, in a monitoring program it is essential
that volatile PAHs such as phenanthrene,
ﬂuoranthene, or pyrene are included.
Biological considerations. The choice of
indicator substances should be based on
both practical and biochemical/biological
considerations. B[a]P has been used tradi-
tionally, and it must still be regarded as the
first choice because of its well-documented
activity as an experimental carcinogen.
When some of the measured PAH com-
pounds in ambient air are assigned TEF
values (potency relative to B[a]P) and their
concentrations are converted into B[a]P
equivalents, B[a]P will, in most cases, be
the main contributor to the carcinogenic
activity.
The WHO risk estimate, 9 × 10–5 per
ng/m3 B[a]P, refers to the total PAH mix-
ture where B[a]P is used as an indicator.
B[a]P should be supplemented with another
indicator to ensure that the risk does not
increase if the composition of the PAH pro-
ﬁle is changed. Preferably it should be a rep-
resentative of more volatile PAHs, as they
are more abundant in ambient air. In the
first instance, we recommend fluoranthene
because it is an experimental mutagen and
carcinogen in certain test systems and it
occurs at relatively high concentrations in
the environment. According to calculations
based on Swedish data, in addition to B[a]P,
ﬂuoranthene can be considered a main con-
tributor to the added carcinogenicity of a
number of PAHs in ambient air. 
The relative contribution of high-
molecular PAHs, such as B[a]P, will proba-
bly decrease in the future when better diesel
technology and qualities have become more
common. The highest concentration of
individual PAH compounds in air samples
from Stockholm is due to phenanthrene.
Both phenanthrene and pyrene, another
abundant PAH, are generally considered
noncarcinogenic, although they have been
assigned TEF values higher than zero by
some authors. They are metabolized in
humans to phenols that can be detected in
urine, and they can thus serve as indicators
for PAH exposure in humans. 
At present, only a few other PAHs have
been identified that are equally or more
potent than B[a]P, for example, dibenz-
[a,h]anthracene. Dibenzopyrenes, in particu-
lar dibenzo[a,l]pyrene, are more potent than
B[a]P (>10-fold). Dibenzo[a,l]pyrene is in
fact the most potent PAH identiﬁed so far.
Up to now there are no Swedish measure-
ment data on dibenzopyrenes, but in a
recent study from California, dibenzo-
[a,l]pyrene was the main contributor to the
B[a]P equivalents. Dibenzo[a,l]pyrene and
dibenz[a]anthrazene are therefore recom-
mended as additional indicator substances.
However, reliable analytic techniques for
dibenzo[a,l]pyrene must be developed for
this purpose.
Other PAHs that contribute substan-
tially to the B[a]P equivalents in Swedish
ambient air are indeno[1,2,3-cd]pyrene and
benzoﬂuoranthenes.
PAHs constitute only part of the larger
group of polycyclic aromatic compounds
that also consists of substituted and trans-
formed PAHs. Some nitro-PAHs have been
fairly well studied, but otherwise there is a
lack of knowledge about the carcinogenicity
of these compounds. Nitro-PAHs could be
used as an indicator of diesel exhaust, but
their instability and difficulties in the mea-
surements may render them less suitable as
indicator substances. Because the muta-
genic activity of particulate extracts from
ambient air mainly resides in the more
polar fractions, it may be suspected that
transformed PAHs also constitute a car-
cinogenic risk. However, when some nitro-
PAHs were considered in TEF calculations
from California, their relative contribution
to the carcinogenicity was minor.
Furthermore, it should be noted that
methylated PAHs constitute a large part of
the analyzed PAHs in the air samples from
Stockholm. The recommended indicators
are summarized in Table 17.
Suggested Guideline Values
The WHO risk estimate, based on lung
cancer in coke-oven workers, can be used to
Special Report • Risk assessment of PAHs in ambient air
Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 3 | JUNE 2002 481recommend a health-based guideline value
for ambient air. However, in the WHO Air
Quality Guidelines for Europe, the unit risk
is used only to express the concentrations in
air that theoretically would lead to lifetime
cancer risks of 1 × 10–4, 1 × 10–5, and 1 ×
10–6, respectively. The individual countries
then have to decide which risk level should
be regarded as acceptable. There is very little
guidance internationally on how to look
upon such low theoretic risks. The EU
Commission provides no recommendations.
In the WHO guidelines for drinking-water
quality (WHO 1996), guideline values for
genotoxic carcinogens are set at the concen-
tration in drinking water associated with an
estimated upper-bound excess lifetime can-
cer risk of 1 × 10–5. Although this risk level
(one additional cancer case per 100,000 of
the population) is arbitrarily chosen, it has
previously been used also at the Institute of
Environmental Medicine in Stockholm to
propose so-called low-risk levels for some
genotoxic carcinogens in the environment. If
the risk level of 1 × 10–5 is chosen also in the
present context, the WHO risk estimate for
PAHs in air would lead to a guideline value
of 0.1 ng/m3 B[a]P as an indicator of the
PAH mixture.
As discussed above, B[a]P should be
supplemented with an indicator of the
more volatile fraction of the PAH mixture
to prevent any increased risks in the case of
a relative increase of volatile PAHs in the
future. As the guideline for B[a]P refers to
the total PAH mixture, a guideline for a
complementary indicator should be set at a
concentration that represents the same risk
as B[a]P does at 0.1 ng/m3. Of the volatile
PAHs, fluoranthene could be a suitable
indicator substance. Fluoranthene is an
experimental carcinogen in newborn mice,
but the limited number of studies prevents
too far-reaching conclusions regarding its
potential carcinogenicity. There are no
epidemiologic studies linking fluoranthene
to an increased cancer risk in humans.
Nevertheless, it has been assigned a TEF
value relative to B[a]P of 0.05, based on the
tests in newborn mice. Such a TEF would
render fluoranthene the second most
important PAH among a selected number
of PAHs, according to Swedish measure-
ments of ambient air. Although the scien-
tific basis for fluoranthene as an indicator
of carcinogenic PAH is much weaker than
that for B[a]P, fluoranthene may serve as a
complementary indicator. Thus, assuming
that the carcinogenic potency of fluoran-
thene is approximately 20 times lower than
that of B[a]P, a tentative guideline value of
2 ng/m3 is suggested for fluoranthene
(Table 18). It should be stressed that the
risks from B[a]P and fluoranthene (or any
other carcinogenic PAH) should not be
added, as they both represent the total can-
cer risk of the PAH mixture (1 × 10–5 at
0.1 ng/m3 B[a]P, or less well based,
2 ng/m3 ﬂuoranthene).
Research Needs
Any quantitative risk assessment of PAHs in
ambient air will be hampered by any serious
weaknesses in the basis for the calculations.
Specifically designed epidemiologic studies
are needed to address the quantitative
aspects relating lung cancer risks to B[a]P or
PAHs in different environments. 
The development of markers for carcino-
genic risk among volatile PAHs is of interest.
For example, the carcinogenicity of ﬂuoran-
thene should be studied in relevant test sys-
tems, and any relation to human cancer
investigated in epidemiologic studies.
Although PAHs have long been recog-
nized as carcinogenic environmental pollu-
tants, only inadequate animal inhalation
studies are so far available. Many of the most
common PAHs analyzed in ambient air
apparently have not been tested in animal
experiments at all. 
Methods for cancer risk estimation of
PAHs (individual compounds or whole mix-
ture) must be further developed and applied
ﬁrsthand to the individual PAHs selected as
indicator compounds for carcinogenicity.
Speciﬁc biological markers of PAH expo-
sure and individual susceptibility are needed
for monitoring purposes. Methods to iden-
tify and quantify specific PAH adducts to
DNA and protein need to be further devel-
oped. 
Better knowledge of exposure–target
dose relationships of PAHs is needed, both
concerning realistic exposures to humans,
and at the much higher exposure levels at
which most in vivo/in vitro biological experi-
ments with PAHs are conducted. In particu-
lar, hidden nonlinearities between exposure
and target dose of PAHs may greatly hamper
both efforts to extrapolate from high-dose
animal experiments to realistic human expo-
sures, efforts to interpret biomarkers of
exposure to PAHs.
Studies on mechanisms and dose–
response relationships for promoter action of
PAHs should be performed, including the
inﬂuence of other promoters—for example,
those acting by interaction or additivity.
There is a general lack of knowledge
about the large group of substituted and
transformed PAHs except for some nitro-
PAHs. Effective mutagens and potential car-
cinogens among substituted (i.e., more
polar) PAHs should be identified in emis-
sions and in air pollution.
A selection of PAHs, including those
compounds recommended in this report,
should be more regularly measured to
acquire more information about concentra-
tions and trends. In addition, the distribu-
tion of PAHs of different particle sizes is of
interest.
Dibenzopyrenes should be analyzed, and
the analytic methods should therefore be
developed. The analytic techniques for nitro-
PAHs should be developed to facilitate their
possible use as indicators.
The importance of wood combustion
should be validated with measurements in
areas/regions where wood is used for heating
purposes.
The possible role of the precipitation of
airborne particles as a source of PAHs in
foodstuffs should be clariﬁed.
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Table 17. Summary of PAHs and related substances recommended for inclusion in ambient air monitoring.
Substance Physical state Reason for selection
Abundance
Phenanthrene Volatile High concentration
Methylated anthracenes/ Volatile High concentration
phenanthrenes
Pyrene Semivolatile High concentration
Carcinogenicity
Fluoranthene Volatile High concentration, carcinogenic
B[a]P Particulate bound Carcinogenic, well studied
Dibenz[a,h]anthracene Particulate bound Carcinogenic
Dibenzo[a,l]pyrene  Particulate bound Strongly carcinogenic
Benzo[b and k]ﬂuoranthene Particulate bound Carcinogenic; indicator of petrol exhaust
Indeno[1,2,3-cd]pyrene Particulate bound Carcinogenic; indicator of petrol exhaust
Source speciﬁcity
Retene Semivolatile Indicator of wood combustion emissions
Dibenzothiophene Semivolatile Indicator of sulfur-containing fuel (diesel exhaust)
Benzonaphthothiophene Semivolatile Indicator of sulfur-containing fuel (diesel exhaust)
Benzo[ghi]perylene Particulate bound Indicator of petrol exhaust
Table 18. Main suggested indicators and guide-
line values.
PAH Guideline value
B[a]P 0.1 ng/m3
Fluoranthene 2 ng/m3 (tentative)Endocrine Disruptors • Risk assessment of PAHs in ambient air
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Appendix. Selected polycyclic aromatic hydrocarbons and polycyclic aromatic heterocycles containing sulfur.
Molecular CAS registry 
Formula weight number Chemical structure Other names
Polycyclic aromatic hydrocarbons 
Phenanthrene C14H10 178 85-01-8  Phenanthrin
Anthracene C14H10 178  120-12-7  Anthracin; green oil; paranaphthalene
2-Methylanthracene C15H12 192 613-12-7 
1-Methylphenanthrene C15H12 192 832-69-9 
Fluoranthene C16H10 202 206-44-0  Benzo[jk]ﬂuorene; idryl; 1,2-benzacenaphthene;
1,2-(1,8-naphthalenediyl)benzene
Pyrene C16H10 202 129-00-0  Benzo[def]phenanthrene
Chrysene C18H12 228 218-01-9  Benzo[a]phenanthrene; 1,2-benzophenanthrene
Benz[a]anthracene C18H12 228 56-55-3  Benzo[b]phenanthrene; tetraphene; 1,2-benzanthracene;
1,2-benzanthrene; 2,3-benzophenanthrene;
naphthanthracene
Retene C18H18 234 483-65-8 1-Methyl-7-isopropylphenanthrene;  7-isopropyl-1-
methylphenanthrene; 1-methyl-7-(1-
methylethyl)phenanthrene
Benzo[a]pyrene C20H12 252 50-32-8  Benz[a]pyrene; 1,2-benzpyrene; 3,4-benzopyrene; 
6,7-benzopyrene; benzo[def]chrysene 
Benzo[e]pyrene C20H12 252 192-97-2  4,5-Benzopyrene;  4,5-benzpyrene
Benzo[k]ﬂuoranthene C20H12 252 207-08-9  Dibenzo[b,jk]ﬂuorene; 11,12-benzoﬂuoranthene;
2,3,1’,8’-binaphthylene; 8,9-benzoﬂuoranthene
Benzo[b]ﬂuoranthene C20H12 252 205-99-2 Benz[e]acephenanthrylene; benzo[e]ﬂuoranthene; 
2,3-benzoﬂuoranthrene; 3,4-benzoﬂuoranthene; 
3,4-benz[e]acephenanthrylene
Benzo[ghi]perylene C22H12 276 191-24-2  1,12-Benzoperylene
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